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A B S T R A C T
Background
This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.
Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal
blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. Systemic
and topical antibiotics are used with the aim of eliminating infection in the short term (and some to reduce inflammation in the long
term), in order to normalise nasal mucus and improve symptoms.
Objectives
To assess the effects of systemic and topical antibiotics in people with chronic rhinosinusitis.
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; CENTRAL (2015, Issue 8); MEDLINE;
EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 29
September 2015.
Selection criteria
Randomised controlled trials (RCTs) with a follow-up period of at least threemonths comparing systemic or topical antibiotic treatment
to (a) placebo or (b) no treatment or (c) other pharmacological interventions.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related
quality of life (HRQL), patient-reported disease severity and the commonest adverse event - gastrointestinal disturbance. Secondary
outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events
of suspected allergic reaction (rash or skin irritation) and anaphylaxis or other very serious reactions. We used GRADE to assess the
quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included five RCTs (293 participants), all of which compared systemic antibiotics with placebo or another pharmacological inter-
vention.
The varying study characteristics made comparison difficult. Four studies recruited only adults and one only children. Three used
macrolide, one tetracycline and one a cephalosporin-type antibiotic. Three recruited only patients with chronic rhinosinusitis without
nasal polyps, one recruited patients with chronic rhinosinusitis with nasal polyps and one had a mixed population. Three followed up
patients for 10 to 12 weeks after treatment had finished.
Systemic antibiotics versus placebo
Three studies compared antibiotics with placebo (176 participants).
One study (64 participants, without polyps) reported disease-specific HRQL using the SNOT-20 (0 to 5, 0 = best quality of life). At
the end of treatment (three months) the SNOT-20 score was lower in the group receiving macrolide antibiotics than the placebo group
(mean difference (MD) -0.54 points, 95% confidence interval (CI) -0.98 to -0.10), corresponding to a moderate effect size favouring
antibiotics (moderate quality evidence). Three months after treatment, it is uncertain if there was a difference between groups.
One study (33 participants, with polyps) provided information on gastrointestinal disturbances and suspected allergic reaction (rash or
skin irritation) after a short course of tetracycline antibiotic compared with placebo. We are very uncertain if antibiotics were associated
with an increase in gastrointestinal disturbances (risk ratio (RR) 1.36, 95% CI 0.22 to 8.50) or skin irritation (RR 6.67, 95% CI 0.34
to 128.86) (very low quality evidence).
Systemic antibiotics plus saline irrigation and intranasal corticosteroids versus placebo plus saline irrigation and intranasal
corticosteroids
One study (60 participants, some with and some without polyps) compared a three-month course of macrolide antibiotic with placebo;
all participants also used saline irrigation and 70% used intranasal corticosteroids. Disease-specific HRQL was reported using SNOT-
22 (0 to 110, 0 = best quality of life). Data were difficult to interpret (highly skewed and baseline imbalances) and it is unclear if there
was an important difference at any time point (low quality evidence). To assess patient-reported disease severity participants rated
the effect of treatment on a five-point scale (-2 for “desperately worse” to 2 for “cured”) at the end of treatment (three months). For
improvement in symptoms there was no difference between the antibiotics and placebo groups; the RR was 1.50 (95% CI 0.81 to
2.79; very low quality evidence), although there were also slightly more people who felt worse after treatment in the antibiotics group.
There was no demonstrable difference in the rate of gastrointestinal disturbances between the groups (RR 1.07, 95% CI 0.16 to
7.10). General HRQL was measured using the SF-36. The authors stated that there was no difference between groups at the end of
treatment (12 weeks) or two weeks later.
Systemic antibiotics versus intranasal corticosteroids
One study (43 participants, without polyps) compared a three-month course of macrolide antibiotic with intranasal corticosteroids.
Patient-reported disease severity was assessed using a composite symptom score (0 to 40; 0 = no symptoms). It is very uncertain if
there was a difference as patient-reported disease severity was similar between groups (MD -0.32, 95% CI -2.11 to 1.47; low quality
evidence).
Systemic antibiotics versus oral corticosteroids
One study (28 participants, with polyps) compared a short course of tetracycline antibiotic (unclear duration, ~20 days) with a 20-day
course of oral corticosteroids. We were unable to extract data on any of the primary efficacy outcomes. It is uncertain if there was a
difference ingastrointestinal disturbances (RR 1.00, 95% CI 0.16 to 6.14) or skin irritation (RR 2.00, 95% CI 0.20 to 19.62) as the
results for these outcomes were similar between groups (very low quality evidence).
Authors’ conclusions
We found very little evidence that systemic antibiotics are effective in patients with chronic rhinosinusitis. We did find moderate quality
evidence of a modest improvement in disease-specific quality of life in adults with chronic rhinosinusitis without polyps receiving three
months of a macrolide antibiotic. The size of improvement was moderate (0.5 points on a five-point scale) and only seen at the end of
the three-month treatment; by three months later no difference was found.
Despite a general understanding that antibiotics can be associated with adverse effects, including gastrointestinal disturbances, the
results in this review were very uncertain because the studies were small and few events were reported.
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No RCTs of topical antibiotics met the inclusion criteria.
More research in this area, particularly evaluating longer-term outcomes and adverse effects, is required.
P L A I N L A N G U A G E S U M M A R Y
Systemic and topical antibiotics for chronic rhinosinusitis
Review question
We reviewed the evidence for the benefits and harms of systemic (given by mouth) or topical (given by nose) antibiotics for people with
chronic rhinosinusitis.
Background
Chronic rhinosinusitis is a common condition that is defined as inflammation of the nose and paranasal sinuses (a group of air-filled
spaces behind the nose, eyes and cheeks). Patients experience at least two or more of the following symptoms for at least 12 weeks:
blocked nose, discharge from their nose or runny nose, pain or pressure in their face and/or a reduced sense of smell (hyposmia). Some
people will also have nasal polyps, which are grape-like swellings of the normal nasal lining inside the nasal passage and sinuses.
Study characteristics
We included five randomised controlled trials (RCTs) with a total of 293 participants. The studies were small (43 to 79 participants).
Four recruited adults and the fifth children. Three studies only included people with chronic rhinosinusitis without nasal polyps, one
a mix of people with and without polyps and the remaining study only people with polyps. All used different types of oral antibiotics;
none looked at topical antibiotics. The antibiotics were given to patients as either antimicrobial or anti-inflammatory agents and for
different lengths of time, although in all cases we were able to look at the outcomes after three months. Antibiotics were compared
with placebo, with intranasal (in the nose) steroids or with oral steroids. One study used antibiotics as an additional treatment, on top
of nasal saline irrigation and most people also took intranasal steroids in this study.
Key results and quality of the evidence
When compared to a placebo (three studies), there was moderate quality evidence in one study that there may be an improvement in
disease-specific health-related quality of life (HRQL) with oral antibiotics in people with chronic rhinosinusitis (without polyps) at the
end of treatment (three months), but it is unclear if HRQL was still improved three months later. There may have been an increase in
gastrointestinal disturbances and suspected allergic reaction (rash or skin irritation) with antibiotics but we are very uncertain and the
quality of the evidence is very low.
Antibiotics were used alongside nasal saline irrigation and intranasal steroids (compared to placebo plus the same) in one study. It is not
clear if there was an important difference in disease-specific HRQL after treatment (three months) or at three months after treatment
was completed (low quality evidence). There may have been more people in the antibiotics group who felt they had ’improved’ at the
end of treatment, but there were also people who had worse symptoms in both groups (very low quality evidence). It is very uncertain
if there was a difference in gastrointestinal disturbances between groups.
When compared with intranasal steroids in people with chronic rhinosinusitis (without polyps), it was very uncertain if there was
a difference in disease severity (using a combined score for four different symptoms) between the antibiotics and intranasal steroids
groups in one study (low quality evidence). No information was given about adverse events.
The one study that compared antibiotics with oral steroids (in people with chronic rhinosinusitis with polyps) did not present any
effectiveness results that we could use. It was uncertain if there was any difference in gastrointestinal disturbances or skin irritation in
the antibiotics group (very low quality evidence).
There were no reports of any serious adverse effects in any of the studies.
Conclusions
We found very little evidence that oral antibiotics are effective in patients with chronic rhinosinusitis. We did find moderate quality
evidence of a modest improvement in disease-specific quality of life in adults with chronic rhinosinusitis without polyps receiving three
months of a macrolide antibiotic. The size of the improvement was moderate (0.5 points on a five-point scale) and only seen at the
end of the three-month treatment; by three months later no difference was found.
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Despite a general understanding that antibiotics can be associated with adverse effects, including gastrointestinal disturbances, the
results in this review were very uncertain because the studies were small and few events were reported.
More research in this area, particularly evaluating longer-term outcomes and adverse effects, is required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Systemic antibiotics compared with placebo for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Intervention: systemic ant ibiot ics
Comparison: placebo
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
Without systemic an-
tibiotics
With systemic antibi-
otics
Difference
Disease-specif ic HRQL
assessed with: SNOT-
20
Scale f rom: 0 to 5
Follow-up: af ter treat-
ment (3 months) and 3
months af ter treatment
has ended (6 months)
of part icipants: 64
(1 RCT)
- • At 3 months: the
mean SNOT-20 score
was 2.88
• At 6 months: the
mean SNOT-20 score
was 2.84
• At 3 months: the
mean SNOT-20 score in
the intervent ion group
was 0.54 lower (0.98
lower to 0.1 lower)
• At 6 months: the
mean SNOT-20 score in
the intervent ion group
was 0.35 lower (0.81
lower to 0.11 higher)
• At 3 months: MD
0.54 lower (0.98 lower
to 0.1 lower)
• At 6 months MD 0.
35 lower (0.81 lower to
0.11 higher)
⊕⊕⊕©
MODERATE 1
• SNOT-20 was
scored with a
maximum of 5 points.
Lower scores in the
group with macrolide
ant ibiot ics indicate a
better quality of lif e at
3 months. The mean
dif ference corresponds
to a moderate ef fect
size (SMD = 0.62),
favouring the
ant ibiot ics group.
• At 6 months (3
months af ter treatment
has ended) it is
uncertain whether
there is a dif ference in
quality of lif e between
the macrolide
ant ibiot ics and placebo
groups and it is
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unlikely that the
dif ference is clinically
important. The mean
dif ference corresponds
to a small ef fect size
(SMD = 0.37).
Disease severity -
pat ient-reported symp-
toms
None of the studies reported this as an outcome
Gastrointest inal distur-
bances
Follow-up: 3 months
of part icipants: 33
(1 RCT)
RR 1.36
(0.22 to 8.50)
Study populat ion ⊕©©©
VERY LOW 2
It is uncertain whether
there is an increase in
gastrointest inal distur-
bances with ant ibiot ics105 per 1000 143 per 1000
(23 to 895)
38 more per 1000
(82 fewer to 789 more)
General health-related
quality of lif e
None of the studies reported this as an outcome
Suspected allergic re-
act ion (rash or skin irri-
tat ion)
Follow-up: 3 months
of part icipants: 33
(1 RCT)
RR 6.67
(0.34 to 128.86)
Study populat ion ⊕©©©
VERY LOW 2
It is uncertain whether
there is an increase in
skin irritat ion with an-
t ibiot ics
No events were re-
ported in the control
arm.0 per 1000
Anaphylaxis or other
very serious react ions
(e.g. Stevens-Johnson
syndrome)
Follow-up: 3 months
of part icipants: 33
(1 RCT)
No events were reported in either arm. The ef fect size could not be est imated
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval;HRQL: health-related quality of lif e; M D: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; SD: standard deviat ion; SM D: standardised
mean dif ference; SNOT-20: Sino-Nasal Outcome Test-20
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded to moderate quality due to imprecision: small sample size (n = 64) leading to imprecise results.
2Downgraded to low quality due to lim itat ions of study design (lack of information about randomisat ion, allocat ion concealment
and blinding, high risk of report ing bias) and imprecision (small study (n = 33) with low number of events leading to large
conf idence intervals).
3Downgraded to very low quality due to lim itat ions of study design (lack of information about randomisat ion, allocat ion
concealment and blinding, high risk of report ing bias), indirectness of the included populat ion and intervent ion (study included
a populat ion who were more severely af fected; those with recurrent polyps or recalcit rant disease; and the intervent ion was a
20-day course of ant ibiot ics) and imprecision (small study (n = 33) with no events in either arm).
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B A C K G R O U N D
Description of the condition
Chronic rhinosinusitis is defined as inflammation of the nose and
paranasal sinuses. It is characterised by two or more symptoms,
one of which must be nasal blockage/obstruction/congestion or
nasal discharge (anterior/posterior nasal drip). The other possible
symptoms include facial pain/pressure, reduction or loss of sense
of smell (in adults) or cough (in children). Symptoms must have
continued for at least 12 weeks. In addition, people must have
either mucosal changes within the ostiomeatal complex or sinuses
(or both) as evidenced by a computerised tomography (CT) scan
and/or endoscopic signs of at least one of the following: nasal
polyps,mucopurulent discharge primarily from themiddlemeatus
or oedema/mucosal obstruction primarily in the middle meatus
(EPOS 2012).
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptoms, including
nasal obstruction, nasal discharge, facial pain, anosmia and sleep
disturbance, have a major impact on quality of life, reportedly
greater in several domains of the SF-36 than angina or chronic res-
piratory disease (Gliklich 1995). Acute exacerbations, inadequate
symptom control and respiratory disease exacerbation are com-
mon. Complications are rare, but may include visual impairment
and intracranial infection.
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore potential differences
between them.
The most commonly used interventions for chronic rhinosinusitis
are used either topically (sprayed into the nose) or systemically (by
mouth) and include steroids, antibiotics and saline.
Description of the intervention
Various groups of systemic antibiotics have been studied in
the treatment of chronic rhinosinusitis, including penicillins,
cephalosporins, quinolones, tetracyclines and macrolides. The du-
ration of antibiotic courses ranges from nine days to 12 weeks.
Topical antibiotics have also been used to treat chronic rhinosi-
nusitis. These have been delivered as antibiotic nasal washes and
sprays.
How the intervention might work
Systemic and topical antibiotics are used in chronic rhinosinusitis
with the aim of eliminating infection and inflammation, normal-
ising the rheology and cohesivity of nasal mucus (Hatipoglu 2005;
Inamura 2000; Miyanohara 2000; Wallwork 2006), altering bac-
terial biofilm formation (Wozniak 2004), reversing ostial occlu-
sion and improving symptoms. The macrolide class of antibiotics
has been specifically identified as potentially useful in chronic rhi-
nosinusitis due to the well-documented anti-inflammatory effects
of reducing cytokine activity and in turn reducing airway inflam-
mation and mucus production (Tamaoki 2004), rather than for
its antibacterial action. Topical antibiotics have the theoretical ad-
vantage of acting directly on the site of infection/inflammation
and providing a higher concentration of antibiotic at the target
site, but they have limited penetration into the sinuses in the un-
operated nose.
However, unnecessary antibiotic prescriptions should be avoided.
Adverse effects are not uncommon, including allergy (
MacLaughlin 2000); these are commonly manifested as skin irri-
tation or rashes (and in severe cases as anaphylaxis, Stevens-John-
son syndrome etc.), diarrhoea and abdominal pain (Bucher 2004).
One of the main concerns with antibiotics is that overuse is associ-
ated with increasing resistance to antibiotics among community-
acquired pathogens.
Why it is important to do this review
Antibiotics are still frequently used to treat patients with chronic
rhinosinusitis. This may be in the mistaken belief that in some
patients with chronic rhinosinusitis some or all of their symptoms
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are related to the presence of pus in their sinuses or nasal secre-
tions, or that ’sinus pain’ is inevitably caused by ’sinus infection’.
This review incorporates an update of a previous Cochrane re-
view (Piromchai 2011), which evaluated systemic antibiotics but
not topical ones. We sought to answer the important question of
whether antibiotics are effective at all for patients with chronic
rhinosinusitis, their relative effectiveness compared to other treat-
ments and whether they are effective as an add-on treatment. We
also tried to find evidence to evaluate which types of antibiotic,
dose or duration of treatment are effective.
This review is one of a suite of Cochrane reviews looking at com-
monmanagement options for patients with chronic rhinosinusitis
(Chong 2016a; Chong 2016b; Chong 2016c; Head 2016a; Head
2016b), and we use the same outcomemeasures across the reviews.
We have not included studies designed to evaluate interventions
in the immediate peri-surgical period, which are focused on as-
sessing the impact of the intervention on the surgical procedure
or on modifying the post-surgical results (preventing recurrence
of chronic rhinosinusitis symptoms).
O B J E C T I V E S
To assess the effects of systemic and topical antibiotics in people
with chronic rhinosinusitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials were only to
be included if the data from the first phase were available); and
• patients were followed up for at least two weeks.
We excluded studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of the intervention on surgical
outcome.
Types of participants
Patients with chronic rhinosinusitis, whether with polyps or with-
out polyps.
We excluded studies that included a majority of patients with:
• cystic fibrosis;
• allergic fungal sinusitis/eosinophilic fungal/mucinous
rhinosinusitis;
• aspirin-exacerbated respiratory disease;
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps;
• primary ciliary dyskinesia;
• a history of surgery for nasal polyps within six weeks of
entry to the study;
• allergic fungal rhinosinusitis/eosinophilic fungal/mucinous
rhinosinusitis; or
• aspirin-exacerbated respiratory disease (aka Samter’s triad).
Types of interventions
We included the following groups of antibiotics:
• macrolides (e.g. clarithromycin, erythromycin);
• tetracyclines (e.g. doxycycline);
• beta-lactams (e.g. penicillins/cephalosporins) with/without
clavulanic acids;
• quinolones.
We included both topically applied and oral antibiotics in the
review. We included any dose and duration of treatment.
We defined short courses of antibiotics as up to 28 days, whereas
we defined long-term courses of antibiotics as longer than four
weeks.
Comparisons
The comparators were:
• placebo or no intervention;
• another class of antibiotics;
• the same type of antibiotic, which is either:
◦ given for a different duration;
◦ given at a different dose;
• other treatments for chronic rhinosinusitis, including:
◦ intranasal corticosteroids;
◦ oral/systemic steroids;
◦ the same type of antibiotic but given for a different
duration;
◦ the same type of antibiotic but given at a different
dose.
Concurrent treatments were allowed if they were used in both
treatment arms; they included:
• nasal saline irrigation only;
• intranasal corticosteroids only;
• intranasal corticosteroids plus nasal irrigation;
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• intranasal corticosteroids plus nasal irrigation plus oral
steroids;
• intranasal corticosteroids plus oral steroids plus antifungal;
• other combinations.
Comparison pairs
There were multiple possible comparison pairs due to the large
number of interventions allowed.
The main comparison pairs of interest were:
• antibiotics versus no intervention or placebo;
• antibiotics plus intranasal steroids or other standard
treatment versus no intervention or placebo plus intranasal
steroids or other standard treatment.
Other possible comparison pairs included:
• antibiotics versus intranasal steroids;
• antibiotics versus oral/systemic steroids;
• antibiotics class A versus antibiotics class B;
• antibiotics plus oral steroids plus intranasal steroids versus
oral plus intranasal steroids;
• antibiotic A with duration of treatment X versus antibiotic
A with duration of treatment Y;
• antibiotic A at dose X versus antibiotic A at dose Y.
This review is part of a larger series of six reviews for the treatment
of chronic rhinosinusitis.
• Intranasal steroids versus placebo or no intervention for
chronic rhinosinusitis (Chong 2016b).
• Different types of intranasal steroids for chronic
rhinosinusitis (Chong 2016a). This review compares different
classes, doses and delivery methods of intranasal corticosteroids
for chronic rhinosinusitis.
• Short-course oral steroids alone for chronic rhinosinusitis
(Head 2016a). This review compares short-course oral steroids
alone with placebo or no intervention, or against other
pharmacological interventions such as antibiotics or nasal saline
irrigation.
• Short-course oral steroids as an adjunct therapy for chronic
rhinosinusitis (Head 2016b). This review compares oral steroids
where they have been used as add-on therapy to other treatments
for chronic rhinosinusitis (such as intranasal corticosteroids,
antibiotics or saline solution).
• Saline irrigation for chronic rhinosinusitis (Chong 2016c).
This review compares nasal saline irrigation for chronic
rhinosinusitis with both placebo/no intervention and with
intranasal corticosteroids or antibiotics.
• Systemic and topical antibiotics for chronic rhinosinusitis
(this review). This review compares both topical and systemic
antibiotics with placebo/no treatment, two different antibiotics
with each other and antibiotics with intranasal corticosteroids.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales). In the absence of validated symptom
score data, patient-reported individual symptom scores were
reported for the following symptoms: nasal obstruction/
blockage/congestion, nasal discharge (rhinorrhoea), facial
pressure/pain, loss of sense of smell (adults) and cough (children).
• Significant adverse effect: gastrointestinal disturbances
include nausea and vomiting, diarrhoea and abdominal pain.
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other adverse effects: suspected allergic reaction (rash or
skin irritation).
• Other adverse effects: anaphylaxis or other very serious
reactions (e.g. Stevens-Johnson syndrome).
• Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Mackay/Lund-
Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
Both short-term (at the end of treatment) and long-term effects are
important therefore we evaluated outcomes at the end of treatment
or within three weeks, at three to six months, six to 12 months
and more than 12 months. For adverse events, we analysed data
from the longest time periods.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 29 September 2015.
Electronic searches
The Information Specialist searched:
• the Cochrane Register of Studies ENT Trials Register
(searched 29 September 2015);
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• the Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 8);
• Ovid MEDLINE (1946 to October week 1 2015);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 29 September 2015);
◦ PubMed (as a top up to searches in Ovid MEDLINE)
(searched 29 September 2015);
• Ovid EMBASE (1974 to 2015 week 41);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies) (searched 29 September 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (searched 29 September 2015);
• Google Scholar (searched 29 September 2015).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, The Cochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we could scan their reference lists
for additional trials.
Data collection and analysis
Selection of studies
At least two review authors independently screened all titles and
abstracts of the studies obtained from the database searches to
identify potentially relevant studies. At least two review authors
evaluated the full text of each potentially relevant study to deter-
mine if it met the inclusion and exclusion criteria for this review.
We resolved any differences by discussion and consensus, with
the involvement of a third author for clinical and/methodological
input where necessary.
Data extraction and management
Two review authors independently extracted data from each study
using a standardised data collection form (see Appendix 2).When-
ever a study had more than one publication, we retrieved all pub-
lications to ensure complete extraction of data. Where there were
discrepancies in the data extracted by different review authors, we
checked these against the original reports and resolved differences
by discussion and consensus, with the involvement of a third au-
thor or amethodologist where appropriate.We contacted the orig-
inal study authors for clarification or for missing data whenever
possible. If differences were found between publications of a study,
we contacted the original authors for clarification. We used data
from the main paper(s) if no further information was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, this included:
• presence or absence of nasal polyps;
• baseline nasal polyp score;
• whether the patient has had previous sinus surgery.
We also noted down whether studies only selected patients with
known bacterial colonisation.
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all patients available at the time points based on
the treatment randomised whenever possible, irrespective of com-
pliance or whether patients had received the treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. Alternatively, if data were available, we planned
to convert into binary data.
We prespecified the time points of interest for the outcomes in
this review. While studies may have reported data at multiple time
points, we only extracted the longest available data within the time
points of interest. For example, for ’short’ follow-up periods, our
time pointwas defined as ’three to sixmonths’ post-randomisation.
If a study had reported data at three, four and six months, we only
extracted and analysed the data for the six-month follow-up.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study. We followed the guidance in the Cochrane Hand-
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book for Systematic Reviews of Interventions (Handbook 2011), and
we used theCochrane ’Risk of bias’ tool.With this tool we assessed
the risk of bias as ’low’, ’high’ or ’unclear’ for each of the following
six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
We summarised the effects of dichotomous outcomes (e.g. propor-
tion of patients with symptom resolution) as risk ratios (RR) with
CIs. For the key outcomes that we presented in the ’Summary of
findings’ table, we also expressed the results as absolute numbers
based on the pooled results and compared to the assumed risk. We
also planned to calculate the number needed to treat to benefit
(NNTB) using the pooled results. The assumed baseline risk is
typically either (a) the median of the risks of the control groups
in the included studies, this being used to represent a ’medium
risk population’ or, alternatively, (b) the average risk of the control
groups in the included studies is used as the ’study population’
(Handbook 2011). If a large number of studies had been available,
and where appropriate, we had also planned to present additional
data based on the assumed baseline risk in (c) a low-risk popula-
tion and (d) a high-risk population.
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD) (we would have
used the standardised mean difference (SMD) if different scales
had been used to measure the same outcome, and we would have
provided a clinical interpretation of the SMD values).
Unit of analysis issues
This review did not use data from phase II of cross-over studies or
from studies where the patient was not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
If we had found cluster-randomised trials, we would have analysed
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We tried to contact study authors via email whenever the outcome
of interest was not reported, if the methods of the study suggested
that the outcome had been measured. We did the same if not all
data required for meta-analysis were reported, unless the missing
data were standard deviations. If standard deviation data were not
available, we approximated these using the standard estimation
methods from P values, standard errors or 95% CIs if these were
reported, as detailed in the Cochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011). Where it was impossible
to estimate these, we contacted the study authors.
Apart from imputations for missing standard deviations, we con-
ducted no other imputations.However, we completed calculations
relating to disease severity (measured by patient-reported symp-
tom scores) as most of the data measured individual symptoms
rather than using validated instruments (see ’Imputing total symp-
tom scores’ below). We extracted and analysed data for all out-
comes using the available case analysis method.
Imputing total symptom scores
Where a paper did not present information for the total dis-
ease severity in terms of patient-reported symptom scores but did
present data for the results of individual symptoms, we used the
symptoms covering the important domains of the EPOS chronic
rhinosinusitis diagnosis criteria (EPOS 2012), to calculate a total
symptom score. The EPOS 2012 criteria for chronic rhinosinusitis
require at least two symptoms. One of the symptoms must be ei-
ther nasal blockage or nasal discharge; other symptoms can include
facial pressure/pain, loss of sense of smell (for adults) or cough (for
children). Where mean final values or changes from baseline were
presented in the paper for the individual symptoms we summed
these to calculate a ’total symptom score’. We calculated standard
deviations for the total symptom score as if the symptoms were in-
dependent, random variables that were normally distributed. We
acknowledge that there is likely to be a degree of correlation be-
tween the individual symptoms, however we used this process be-
cause the magnitude of correlation between the individual symp-
toms is not currently well understood (no evidence found). If the
correlation is high, the summation of variables as discrete vari-
ables is likely to give a conservative estimate of the total variance
of the summed final score. If the correlation is low, this method
of calculation will underestimate the standard deviation of the to-
tal score. However, the average patient-reported symptom scores
have a correlation coefficient of about 0.5; if this is also applica-
ble to chronic rhinosinusitis symptoms, the method used should
have minimal impact (Balk 2012). As this method of calculation
does not take into account weighting of different symptoms (no
evidence found), we downgraded all the disease severity outcomes
for lack of use of validated scales whenever this occurred.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even
in the absence of statistical heterogeneity) by examining the in-
cluded trials for potential differences between studies in the types
of participants recruited, interventions or controls used and the
outcomes measured.
We would have assessed statistical heterogeneity by visually in-
specting the forest plots and by considering the Chi² test (with a
significance level set at P value < 0.10) and the I² statistic, which
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calculates the percentage of variability that is due to heterogeneity
rather than chance, with I² values over 50% suggesting substantial
heterogeneity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this could be obtained. If the protocol was not available,
we compared the outcomes reported to those listed in themethods
section. If results were mentioned but not reported adequately in a
way that allowed analysis (e.g. the report only mentioned whether
the results were statistically significant or not), bias in a meta-
analysis is likely to occur. We sought further information from
the study authors. If no further information could be obtained,
we noted this as being a ’high’ risk of bias. Quite often there was
insufficient information to judge the risk of bias; we noted this as
an ’unclear’ risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We planned to assess funnel plots if sufficient trials (more than
10) had been available for an outcome. If we had observed asym-
metry of the funnel plot, we had planned to conduct more formal
investigation using the methods proposed by Egger 1997.
Data synthesis
We conducted all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we planned to analyse
treatment differences as a risk ratio (RR) calculated using theMan-
tel-Haenszel methods. We planned to analyse time-to-event data
using the generic inverse variance method.
For continuous outcomes, if all the data were from the same scale,
we had planned to pool mean values obtained at follow-up with
change outcomes and report this as a MD. However, if the SMD
had to be used as an effect measure, we would not have pooled
change and endpoint data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
We had planned to conduct some subgroup analyses regardless of
whether statistical heterogeneity was observed, as these are widely
suspected to be potential effect modifiers. For this review, this
included:
• Phenotype of patients: whether patients have chronic
rhinosinusitis without nasal polyps, chronic rhinosinusitis with
nasal polyps, a mixed group or the status of polyps is not known
or not reported. We planned to undertake the subgroup analysis
as although there appears to be a considerable overlap between
the two forms of chronic rhinosinusitis with regards to
inflammatory profile, clinical presentation and effect of
treatment (Cho 2012; DeMarcantonio 2011; Ebbens 2010;
Fokkens 2007; Ragab 2004; Ragab 2010; van Drunen 2009),
there is some evidence pointing to differences in the respective
inflammatory profiles (Kern 2008; Keswani 2012; Tan 2011;
Tomassen 2011; Zhang 2008; Zhang 2009), and potentially
even differences in treatment outcome (Ebbens 2011). The role
of microbes in the pathology is also unclear and this makes it
uncertain whether antibiotics will have similar effects.
• Class of antibiotics: some antibiotics, such as the
macrolides, are known to have some anti-inflammatory actions
in addition to their antibacterial activity.
We planned to present the main analyses of this review according
to the subgroups of phenotypes of chronic rhinosinusitis. We in-
tended to present all other subgroup analysis results in tables.
When studies had amixed group of patients, we planned to analyse
the study as one of the subgroups (rather than as a mixed group) if
more than 80% of patients belonged to one category. For example,
if 81% of patients had chronic rhinosinusitis without nasal polyps,
we would have analysed the study as that subgroup.
In addition to the subgroups above, we planned to conduct the
following subgroup analyses in the presence of statistical hetero-
geneity:
• patient age (children versus adults);
• dose;
• duration of treatment;
• method of delivery (dependent on review).
Sensitivity analysis
We planned to carry out sensitivity analyses to determine whether
the findings were robust to the decisions made in the course of
identifying, screening and analysing the trials. We planned to con-
duct sensitivity analysis for the following factors, whenever possi-
ble:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we defined these as studies that have a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed);
• how outcomes were measured: we planned to investigate
the impact of including data where the validity of the
measurement was unclear.
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If any of these investigations had found a difference in the size of
the effect or heterogeneity, we would have mentioned this in the
Effects of interventions section.
GRADE and ’Summary of findings’ table
We
used the GRADE approach to rate the overall quality of evidence
using the GDT tool (http://www.guidelinedevelopment.org/) for
the main comparison pairs listed in the Types of interventions sec-
tion. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is correct and we applied this in
the interpretation of results. There are four possible ratings: ’high’,
’moderate’, ’low’ and ’very low’. A rating of ’high’ quality evidence
implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of ’very low’ quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ tables present only the seven top prior-
ity outcomes (disease-specific health-related quality of life, disease
severity score, adverse effects and generic quality of life score). We
did not include the outcomes endoscopic score and CT scan score
in the ’Summary of findings’ tables.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 2761 references (after removal of
duplicates). We screened the titles and abstracts and subsequently
removed 2698 studies. We assessed 63 full texts for eligibility.
We included five studies (six papers) and excluded 47 studies (52
papers). Five studies are awaiting assessment. We identified one
ongoing study.
A flow chart of study retrieval and selection is provided in Figure
1.
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Included studies
There are five studies (six papers) with 293 participants included in
this review (Otten 1994; Van Zele 2010; Videler 2011; Wallwork
2006; Zeng 2011). The important characteristics of these studies
are summarised below.
Design
Four studieswere double-blind, parallel-groupRCTs (Otten 1994;
Van Zele 2010; Videler 2011; Wallwork 2006). One study was an
open-label, parallel-group RCT (Zeng 2011). All of the included
studies had a two-arm design except Van Zele 2010, which used a
three-arm design. All studies had a minimum of 12 weeks follow-
up.
Setting
One study was a single-centre trial conducted in China (Zeng
2011). Two studies were multicentre trials conducted in a single
country: the Netherlands (Otten 1994) and Australia (Wallwork
2006). The remaining two were international, multicentre trials:
Van Zele 2010 took place in five centres in Belgium, Germany,
Holland and Australia and Videler 2011 was conducted in six cen-
tres in the Netherlands, Finland, Belgium, England and Croatia.
Participants and sample sizes
The sample sizes ranged from 43 (Zeng 2011) to 79 participants
(Otten 1994). Four studies included an adult population ranging
in age from20 to 70 years (VanZele 2010; Videler 2011;Wallwork
2006; Zeng 2011), and the last recruited only a paediatric popu-
lation with an age range of 2 to 12 years (Otten 1994).
The European Position Paper on Rhinosinusitis and Nasal Polyps
(EP3OS) diagnostic criteria (EPOS 2007) were used in two stud-
ies (Videler 2011; Zeng 2011). Zeng 2011 only recruited Chinese
people with chronic rhinosinusitis without nasal polyps. Videler
2011 recruited people with recalcitrant chronic rhinosinusitis (ab-
sence of response to standard treatment) both with and without
nasal polyps, although people with nasal polyps assessed as being
equal to 2 or more on a 0 to 3 scale (0 = no polyps, 3 = severe
polyps) were excluded. Nasal polyps were present in 62.1% and
41.9% of participants in the antibiotics and placebo groups, re-
spectively.Wallwork 2006 recruited patients based on the Rhinos-
inusitis Task Force (Lanza 1997); nasal polyps were an exclusion
criterion.
One study recruited participants based on the endoscopic finding
of recurrent bilateral nasal polyps after surgery or massive bilateral
nasal polyps (grade 3 or 4 on a scale of 0 to 4) (Van Zele 2010).
Otten1994 included a paediatric populationwith chronic sinusitis
diagnosed using a combination of clinical signs and symptoms for
more than three months and radiographic findings. Nasal polyps
were an exclusion criterion. The age range was from 2 to 12 years.
All studies had almost equal numbers of male and female partici-
pants (Otten 1994; Van Zele 2010; Videler 2011;Wallwork 2006;
Zeng 2011).
Interventions
Four studies were placebo-controlled (Otten 1994; VanZele 2010;
Videler 2011; Wallwork 2006). One study compared antibiotics
to oral corticosteroids (Van Zele 2010), and one to intranasal
corticosteroids (Zeng 2011).
The antibiotics under investigation were cefaclor (Otten 1994),
roxithromycin (Wallwork 2006), azithromycin (Videler 2011),
clarithromycin (Zeng 2011), and doxycycline (Van Zele 2010).
Otten 1994 compared cefaclor at a dose of 20 mg/kg/day di-
vided into three equal doses for one week with placebo. Wallwork
2006 compared roxithromycin 150 mg daily for three months
with placebo. Videler 2011 compared oral azithromycin 500 mg
per day for three days, then 500 mg per week for 11 weeks with
placebo. Zeng 2011 compared oral clarithromycin 250 mg once
daily for 12 weeks with mometasone furoate nasal spray 200 µg
once daily for 12 weeks. Van Zele 2010 had two separate com-
parisons (doxycycline versus placebo and doxycycline versus oral
methylprednisolone). Doxycycline was given at 200 mg on day
1, 100 mg/day on days 2 to 20 and oral methylprednisolone was
given at 32 mg/day on days 1 to 5, at 16 mg/day on days 6 to 10
and at 8 mg/day on days 11 to 20.
Three studies mention that participants were not allowed to use
some treatments in the four weeks prior to the trial. Wallwork
2006 excluded people who had used intranasal steroids or oral
steroids, Videler 2011 excluded people who had used oral steroids,
and Zeng 2011 excluded people who had used saline irrigation,
intranasal steroids, oral steroids or macrolide antibiotic treatment.
With regard to concomitant treatments during the trial, Zeng
2011 commented that the patients did not receive other additional
treatments during the trial and two studies made no mention
of other treatments (Otten 1994; Wallwork 2006). Both study
groups in Videler 2011 received nasal saline irrigation and Otten
1994 comments that saline was used to aspirate pus for cultures.
Where no mention of additional treatment was made it is possible
that the participants performed saline irrigations as it was neither
specifically included nor excluded (Otten 1994; Van Zele 2010;
Wallwork 2006).
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Two trials provided information on concomitant intranasal steroid
treatment: in Van Zele 2010 the use of concomitant intranasal
steroids during the treatment phase was not allowed, although the
authors state that it was allowed as rescue medication in the fol-
low-up period once the treatment phase had been completed. The
second trial, Videler 2011, allowed concurrent intranasal steroids
providing the dose was kept constant throughout study and re-
ported that 70% of the patients received intranasal steroids.
Outcomes
Disease-specific health-related quality of life
This was measured in two studies (Videler 2011;Wallwork 2006).
Videler 2011 used the Sinonasal Outcome Test-22 (SNOT-22)
score (range: 0 to 110), measured at baseline, 14 and 24 weeks,
whereas Wallwork 2006 used the Sinonasal Outcome Test-20
(SNOT-20) (range: 0 to 5) at pre-treatment, at 12 weeks imme-
diately after treatment and at 24 weeks (12 weeks post treatment).
Disease severity - symptoms score
Three studies presented information about disease severity in terms
of symptom scores (Van Zele 2010; Videler 2011; Zeng 2011).
Van Zele 2010 used a disease severity score, measured by patient-
assessed symptoms (anterior rhinorrhoea, nasal obstruction, post-
nasal drip and loss of sense of smell) at 20 days and 12 weeks
although details of the scales used to record symptoms are not
provided within the paper.
Videler 2011 evaluated the symptoms of headache, nasal obstruc-
tion, rhinorrhoea, post-nasal drip, feeling of fullness, smell distur-
bance, facial pain, toothache, tears, coughing, nasal bleeding and
crusts on a 0 to 10 visual analogue scale (VAS) at 12 weeks. The
study also reported an overall change in symptoms using “Patient
ResponseRating Scale” to classify the subjective effect of the course
(-2 desperately worse (deterioration of symptoms with significant
impact on normal life); -1 worse (compared with the pretreatment
situation); 0 no change; 1 improvement (although symptoms are
present, they are scarcely troublesome); and 2 cured (virtually no
symptoms present)).
Zeng 2011 scored five symptoms (nasal obstruction, rhinorrhoea,
loss of sense of smell, facial pain or pressure, headache) using a 0
to 10 VAS at 0, 4, 8 and 12 weeks.
General health-related quality of life
This was measured in one study, Videler 2011, which used the
Short Form-36 (SF-36) instrument at baseline, 14 and 24 weeks.
Endoscopic scores (including nasal polyps score)
Four studies recorded endoscopic scores (Van Zele 2010; Videler
2011; Wallwork 2006; Zeng 2011). Three of these looked at
overall endoscopic findings (Videler 2011; Wallwork 2006; Zeng
2011).One study used the validated Lund-Kennedy score measur-
ing swelling and discharge (Zeng 2011). The other studies did not
provide information about validation of the scales used (Videler
2011; Wallwork 2006). One study only assessed the size of the
nasal polyps (Van Zele 2010). The measurements were made pre-
treatment and after treatment (12 weeks) in all studies (Van Zele
2010; Videler 2011; Wallwork 2006; Zeng 2011).
Computerised tomography (CT) scan score
No studies provided results for this outcome.
Adverse effects
Two studies reported information on adverse events (Van Zele
2010; Videler 2011). Van Zele 2010 recorded gastrointestinal dis-
turbances (reflux or gastric pain, or both), and skin irritation (skin
rash). No studies reported anaphylaxis or other serious allergic re-
actions such as Stevens-Johnson syndrome. Videler 2011 reported
that there were no serious adverse effects and reported gastroin-
testinal disturbances (mostly mild diarrhoea). No other studies
made any comment about adverse events.
Funding and conflict of interests in trials
No information about funding for the trial was provided in two
studies (Otten 1994; Wallwork 2006). In one the study medica-
tion was provided by the pharmaceutical company but no fur-
ther information was provided (Videler 2011). The remaining two
studies were funded by what appear to be academic or governmen-
tal grants (Van Zele 2010; Zeng 2011).
Two studies did not provide information on any potential conflicts
of interest of investigators within the trials (Otten 1994;Wallwork
2006). Two stated that they knew of no known conflicts of interest
(Videler 2011; Zeng 2011). One reported that one author had
received royalties from a medical device company and was a con-
sultant for another company (NeilMed). This author, along with
two other authors, received research grants from external bodies
(Garnett Passe and Rodney Williams Foundation, GlaxoSmithK-
line, Stallergenes, European Union) (Van Zele 2010).
Excluded studies
We excluded 47 studies (52 papers) after reviewing the full paper.
Further details of the reasons for exclusion are summarised in
Characteristics of excluded studies.
We excludedmost of the studies (32) due to the duration of follow-
up in the trial not meeting the minimum criteria (three months)
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as set out in the review protocol inclusion criteria (Agbim 1975;
Amini 2009 Ansari 2015; Artigas 1989; Beloborodova 1998;
Bonfils 2015; Dellamonica 1994; Desrosiers 2001; Edelstein
1993; El’kun 1999; Fan 2014; Huck 1993; Husfeldt 1993;
Jareoncharsri 2004; Jervis-Bardy 2012; Jiang 2008; Korkmaz
2014; Kunel’skaya 2008; Legent 1994; Li 2000; Li 2002; Li 2014;
Mannhardt 1980; Namyslowski 1998; Peric 2011; Portier 1996;
Rachelefsky 1982; Sreenath 2015; Sykes 1986; Videler 2008;
Watanabe 2003; Wei 2011). Of these studies, 18 followed up par-
ticipants for one month or less (Agbim 1975; Ansari 2015; Artigas
1989; Beloborodova 1998; Edelstein 1993; El’kun 1999; Huck
1993;Husfeldt 1993; Jareoncharsri 2004; Jervis-Bardy 2012; Jiang
2008; Kunel’skaya 2008; Li 2014;Mannhardt 1980; Portier 1996;
Rachelefsky 1982; Sykes 1986; Watanabe 2003). These studies
generally included a mixed population of acute sinusitis and par-
ticipants with acute exacerbations of chronic sinusitis. Participants
were randomised to a short course of oral steroids (7 to 14 days)
and followed up at the end of the treatment period or up to two
weeks after treatment. Seven studies followed up patients for four
to eightweeks (Bonfils 2015;Dellamonica 1994; Fan 2014; Legent
1994; Namyslowski 1998; Sreenath 2015; Wei 2011), and four
studies for between eight to 12 weeks (Amini 2009; Desrosiers
2001; Korkmaz 2014; Peric 2011). There were three studies where
the duration of follow-up was not clear (Li 2000; Li 2002; Videler
2008); this included one study that was a cross-over trial (Videler
2008). In this study the outcomes were reported after the first
phase at between 8 to 12 weeks, but the precise timing was not
clear. In addition, the results of the first and second phase were
reported together and it was not possible to separate these out. We
attempted to contact the study author for further information but
could not establish contact.
We excluded nine studies because the study aims were to in-
vestigate the effectiveness of antibiotics in the perioperative,
or immediate postoperative, period (Amali 2015; Bobacheva
2012; Chatzimanolis 1998; Haxel 2015; Hiratsuka 1996;
NCT01825408; NCT02307825; Schalek 2009; Varvianskaia
2013).
Three studies made comparisons that were not relevant to this
review (Hashiba 1997; IRCT201312299014N; Otten 1997).
Hashiba 1997 compared clarithromycin with erythromycin,
which were both the same class of antibiotic and, therefore, ex-
cluded from the review. IRCT201312299014N is an ongoing trial
that will compare phonophoresis of erythromycin with pulsed ul-
trasound. Otten 1997 compared four different interventions: xy-
lometazoline (nasal decongestant) plus antibiotics and drainage,
drainage plus xylometazoline plus antibiotics, and a placebo arm.
We excluded two studies due to the design of the study (Bezerra
2014; Kita 1995): both were non-randomised controlled trials.
We excluded one study as the included population were those with
sinobronchial syndrome (Ishiura 1995).
Studies awaiting assessment
There are five studies awaiting assessment. For four studies the full
paper could not be obtained within the timeframe of the review
(Behm 2002; Jiang 2001; Kataoka 2003; Ziuzio 1995), and for
the fifth the length of follow-up in the study was unclear from
the paper (Kim 2003). We have contacted the study author and
we are awaiting a reply. See Characteristics of studies awaiting
classification.
Ongoing studies
We identified one ongoing study (EUCTR 2005 (2005-004736-
51)). See Characteristics of ongoing studies.
Risk of bias in included studies
The included studies were all randomised and controlled. Details
of the risk of bias for each study can be found in Figure 2. A ’Risk
of bias’ graph shows our judgements about each risk of bias item
presented as percentages across all included studies (Figure 3). In
general the reporting of the trials was not of a high quality.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation
We assessed three studies as having a low risk of bias for sequence
generation as the methods were well described (Videler 2011;
Wallwork 2006; Zeng 2011). Two studies did not provide any in-
formation about how patients were randomised (Otten 1994; Van
Zele 2010). In Van Zele 2010, the number of people randomised
was small and there is a risk that the allocation between the groups
many not have been balanced (14 in group 1, 14 in group 2 and
19 in group 3).
Allocation concealment
Four studies did not present any information about the methods
for allocation concealment (Otten 1994;VanZele2010;Wallwork
2006; Zeng 2011). We assessed Videler 2011 to be at low risk of
bias for allocation concealment as the randomisation occurred ex-
ternally and randomised packs were distributed to the participants
who qualified with consecutive numbering.
Baseline characteristics
In two studies there was a lack of information on baseline charac-
teristics of the study participants (Otten 1994; Wallwork 2006),
although Wallwork 2006 did report that there were no differences
between the two groups. Van Zele 2010 reported an imbalance
between the two groups in the number of participants at base-
line with ’allergy’ (oral steroids: 35.7%; placebo: 57.9%; antibi-
otics: 14.3%) and the number who were “aspirin intolerant” (oral
steroids: 14.3%; placebo: 26.3%; antibiotics: 7.1%). These were
not statistically different but it may have been due the sample size
being small (n = 48). The other studies did not find differences
in the baseline characteristics between their study arms (Videler
2011; Zeng 2011).
Blinding
We assessed two studies to be at a low risk of performance and
detection bias as they were both double-blind studies with both
patients and healthcare professionals (outcome assessors) blinded
to the treatment group (Videler 2011; Wallwork 2006).
We assessed two studies as having an unclear risk of bias due
to blinding (Otten 1994; Van Zele 2010). Both studies stated
that they were “double-blind” but did not provide any further
information. Van Zele 2010 provides no information about the
dosing schedule of the three arms within the trial (oral steroids,
placebo and antibiotics) and what precautions were taken to pre-
vent the participants and healthcare professionals from identifying
the treatment arm to which they had been allocated. There was no
information about blinding of outcome assessment in the paper.
Zeng 2011 was an open-label study and so we assessed the risk of
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bias due to blinding as high.
Incomplete outcome data
Three studies were at a low risk of attrition bias with no patients
reported as dropping out of the study in Zeng 2011, a drop-out
rate (with reasons provided) of 5% in Otten 1994, and 8% at the
end of treatment and 12.5% at the follow-up six months from the
start of treatment in Wallwork 2006. There were no significant
differences in drop-out rates between the groups in any study.
We assessed both Van Zele 2010 and Videler 2011 to be at a high
risk of bias due to incomplete outcome data. In Van Zele 2010,
seven of the initial 47 patients dropped out of the study (14.9%)
and an intention-to-treat analysiswas conductedwith the last value
carried forward. However, all of the patients who dropped out
were from the placebo group 7/19 (36.8%). The report implies
that they all dropped out after the treatment stage during follow-
up. This may have had an effect on the overall results and no
sensitivity analysis appears to have been completed to identify
the impact. In Videler 2011, 9/60 participants (15%) did not
complete the study. Reasons for non-completion are given and are
distributed equally between the intervention and placebo group.
No denominator values were given by group at the final time
point, although additional participants dropping out are reported.
Denominator values for measuring adverse events (gastrointestinal
disturbances) are not reported.
Selective reporting
We assessed all of the studies to be at an unclear risk of bias due
to selective reporting (Otten 1994; Van Zele 2010; Videler 2011;
Wallwork 2006;Zeng2011). InVanZele2010,many of the results
were presented graphically, without providing values at key time
periods. The data were not reported in a way that allowed them to
be included in the meta-analysis for this review. Similarly, Videler
2011 did not always present the full results for all outcomes and
these were sometimes reported generally rather than by providing
the data (e.g. endoscopic score). In Otten 1994, the results are not
well presented.
The reporting of adverse events was a particular concern in all of
the studies (Otten 1994; Van Zele 2010; Videler 2011; Wallwork
2006; Zeng 2011). No information about whether there were any
adverse events was given in three studies (Otten 1994; Wallwork
2006; Zeng 2011). Even in those studies that did present adverse
events the methods for recording their measurement were not
described (Van Zele 2010; Videler 2011).
A protocol document could be found for two of the five
studies (Van Zele 2010; Videler 2011). For Van Zele 2010
(NCT00480298), it was difficult to judge whether there were dif-
ferences between the protocol and the full paper as the protocol
was not detailed. In Videler 2011 (EUCTR-2005-001062-14),
there is an additional outcome that is reported in the paper but
not presented in the protocol: patient response scale, which was
not one of the key outcomes in this review. In both cases we noted
that the number of participants that the study aimed to recruit was
different from the number actually recruited: 120 planned and 48
recruited for Van Zele 2010, and 120 planned and 60 recruited
for Videler 2011.
Other potential sources of bias
Use of validated outcome measures
Although the studies reporting health-related quality of life out-
comes used validated instruments (Videler 2011;Wallwork 2006),
the papers generally lacked information on the validation of other
instruments. In particular, the validation of instruments used to
measure ’symptom severity’ was poorly reported.None of the three
studies that reported this outcomementioned validation (Van Zele
2010; Videler 2011; Zeng 2011). In fact, details of the scales used
tomeasure symptomswere not provided inVan Zele 2010. It was a
similar story with regard to the use of validated outcome measures
for the endoscopic outcomes; three studies did not provide infor-
mation on validation (Van Zele 2010; Videler 2011; Wallwork
2006).
Effects of interventions
See: Summary of findings for the main comparison Systemic
antibiotics compared with placebo; Summary of findings
2 Systemic antibiotics plus saline irrigation and intranasal
corticosteroids compared with placebo plus saline irrigation and
intranasal corticosteroids; Summary of findings 3 Systemic
antibiotics compared with intranasal corticosteroids; Summary of
findings 4 Systemic antibiotics comparedwith oral corticosteroids
Where the range of scales and values for minimal important dif-
ferences (MID) were unclear, we used the standardised mean dif-
ference (SMD) as a guide to estimate the effect sizes. As suggested
in the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), we used standard rules of thumb in the inter-
pretation of effect sizes (SMD, or Cohen’s effect size of < 0.41 =
small, 0.40 to 0.70 = moderate, > 0.70 = large) (Cohen 1988).
Established scales such as the Sino-Nasal Outcome Test-22
(SNOT-22) may have other known MID values (MID = 9 points
for SNOT-22) and we used those to guide our interpretation
whenever available (Hopkins 2009). In the absence of a MID, we
used other rules of thumb to estimate this (MID = 0.5 SMD) and
to guide our interpretation whenever available (Jaeschke 1989;
Revicki 2008).
Antibiotics versus placebo
See also Summary of findings for the main comparison.
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Three studies reported on this comparison (Otten 1994; Van Zele
2010; Wallwork 2006). Van Zele 2010 (33 participants) com-
pared a tetracycline (doxycycline) with a placebo in adults with
massive bilateral nasal polyps or bilateral nasal polyps that had
recurred after surgery. Wallwork 2006 (64 participants) compared
a macrolide antibiotic (roxithromycin) with a placebo in adults
with a history consistent with a diagnosis of chronic rhinosinusitis
but without nasal polyps. The remaining paper (79 participants)
compared treatment with a cephalosporin-type antibiotic (cefa-
clor) with placebo in children with chronic sinusitis but did not
report any outcomes relevant to this review (Otten 1994).
Primary outcomes
1. Disease-specific health-related quality of life
One study (64 participants) compared roxithromycin against
placebo treatment using the SNOT-20 instrument to assess qual-
ity of life (range: 0 to 5; 0 = least quality of life, 5 = most quality
of life) at the end of treatment (three months) and three months
after treatment had completed (six months) (Wallwork 2006). At
the end of treatment people with chronic rhinosinusitis without
nasal polyps receiving roxithromycin had an improved quality of
life compared with the placebo group (mean difference (MD) -
0.54, 95%confidence interval (CI) -0.98 to -0.10; 64 participants;
one study). This mean difference equates to a moderate effect size
(SMD = 0.62). At three months after treatment it is very uncer-
tain if there is a difference between the two groups (MD -0.35,
95% CI -0.81 to 0.11; 64 participants; one study). The observed
mean difference corresponds to a small effect size (SMD = 0.37)
(Analysis 1.1).
2. Disease severity, as measured by patient-reported symptom
score
One study in people with chronic rhinosinusitis with nasal polyps
(33 participants) compared doxycyline (duration approximately
20 days) against placebo and measured the following patient-as-
sessed symptoms: anterior rhinorrhoea, nasal obstruction, post-
nasal drip and loss of sense of smell after treatment (20 days) and
12 weeks from the start of the trial (Van Zele 2010). Details of
the scales used to record symptoms are not provided in the paper
and the results are not sufficient to allow them to be used in a
quantitative analysis. We contacted the author but they did not
provide additional information.
3. Significant adverse effect: gastrointestinal disturbances
One study in people with chronic rhinosinusitis with nasal polyps
(33 participants) compared a short course of doxycyline (duration
approximately 20 days) against placebo and reported the adverse
event of “reflux and/or gastric pain” at 12 weeks (Van Zele 2010).
There were a low number of events in both arms: 2/14 in the
doxycycline arm and 2/19 in the placebo arm (RR 1.36, 95% CI
0.22 to 8.50; 33 participants; one study) (Analysis 1.2).
Secondary outcomes
1. General health-related quality of life
This was not reported as an outcome in any study.
2. Other adverse event: suspected allergic reaction (rash or
skin irritation)
One study in people with chronic rhinosinusitis with nasal polyps
(33 participants) reported the adverse event of “skin rash” at 12
weeks after a short course of doxycycline (duration approximately
20 days) (Van Zele 2010). There were very few events in both
arms: 2/14 in the doxycycline arm and 0/19 in the placebo arm
(RR 6.67, 95% CI 0.34 to 128.86; 33 participants; one study)
(Analysis 1.3).
3. Other adverse event: anaphylaxis or other serious allergic
reactions such as Stevens-Johnson syndrome
One study in people with chronic rhinosinusitis with nasal polyps
(33 participants) reported adverse events well and so we assumed
that if an anaphylaxis event or other serious allergic reaction had
occurred, this would have been reported in the paper (Van Zele
2010). We assumed that no events occurred in either arm of the
study. No risk estimate could be provided.
4. Endoscopic scores (including nasal polyps score)
Two studies (97 participants) report the results of endoscopy (Van
Zele 2010;Wallwork 2006). VanZele 2010 (33 participants) com-
pared doxycycline (duration approximately 20 days) with placebo
in people with chronic rhinosinusitis with nasal polyps. Theymea-
sured nasal polyps in each nostril on a five-point scale (0 to 4; 0 =
no polyps, 4 = large polyps). The scores for each nostril were then
added together to get an overall nasal polyp score (final range 0
to 8, 0 = least severe). The paper presented the results graphically
as change from baseline polyps score, however, despite contacting
the author, data on the variance of the point estimates were not
available and it was not possible to impute them. The paper states,
“Administration of doxycycline for 20 days significantly reduced
polyp size, starting at week 2, compared with placebo (visit 3; P
= 0.005). The significant reduction of polyp size remained for up
to 12 weeks after dosing (visit 4, P5.001; visit 5, P = 0.002; and
visit 6, P = 0.015).”
Wallwork 2006 (64 participants) presented the results of an overall
endoscopy score in patients with chronic rhinosinusitis without
nasal polyps. They graded swelling (0 to 2), mucosal colour (0 to
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1), polyps in the middle meatus (0 to 1) and nasal secretions (0 to
3). The final range of values was between 0 and 7 (0 = least severe,
7 = most severe). The results at three months were: MD -0.30
(95% CI -0.85 to 0.25; 64 participants; one study). The observed
mean difference corresponds to a small effect size (SMD = 0.27)
(Analysis 1.4).
We did not present endoscopy scores in the ’Summary of findings’
table as we did not consider this to be a priority outcome.
5. Computerised tomography (CT) scan score
This was not reported as an outcome in any of the studies.
Antibiotics plus saline plus intranasal corticosteroids
versus placebo plus saline plus intranasal
corticosteroids
See also Summary of findings 2.
One study (60 participants) reported on this comparison (Videler
2011). The population included people with chronic rhinosinusi-
tis both with and without nasal polyps. The participants were
a more severely affected population who had not responded to
standard treatment. The study compared a macrolide antibiotic
(azithromycin) for 12 weeks against placebo. All participants in
both arms used nasal saline irrigation twice daily and the data sug-
gest that 70% of patients also received intranasal steroids.
Primary outcomes
1. Disease-specific health-related quality of life
Videler 2011 reported results for health-related quality of life at 14
weeks (53 participants) and six months (51 participants) using the
SNOT-22 outcome measure (range: 0 to 110, 0 = least affected,
110 = most affected). There was a potentially clinically important
difference in the baseline SNOT-22 score between the two groups
(antibiotics score = 48.2, placebo score: 40.0, known MID 8.9
points (Hopkins 2009)). The studies reported both the scores and
change from baseline at 14 weeks (two weeks after the end of
antibiotic treatment) and at six months (three months after the
end of antibiotic treatment).
At 14 weeks (two weeks after the end of antibiotic treatment) the
mean change frombaseline scorewas -3.7 (standard deviation (SD)
16.7) in the antibiotics group and -8.9 (SD 15.6) in the placebo
group. These data are highly skewed and the authors reported no
statistically significant difference using the Mann Whitney U-test
(P value = 0.3).
At six months (three months after the end of antibiotic treatment)
the mean change from baseline score was -8.5 (SD 20.3) in the
antibiotics group and -5.2 (SD 18.9) in the placebo group (Mann
Whitney U-test P value = 0.528).
Since the data were highly skewed and parametric tests did not
detect a statistically significant difference, it is uncertain whether
there is a difference between groups.
2. Disease severity, as measured by patient-reported symptom
score
Global change of symptom score
The study used a “Patient Response Rating Scale” (validation not
reported) to classify the subjective effect of the course (-2 desper-
ately worse (deterioration of symptoms with significant impact on
normal life); -1 worse (compared with the pretreatment situation);
0 no change; 1 improvement (although symptoms are present,
they are scarcely troublesome); and 2 cured (virtually no symp-
toms present)). We dichotomised the score into the proportion
of patients who had improved (categorising patients who scored
“improvement” and “cured” as improved). There was no differ-
ence between the antibiotics and placebo groups; the risk ratio for
improvement was 1.50 (95% CI 0.81 to 2.79; 56 participants;
one study) (Analysis 2.1). The quality of the evidence is very low.
Individual symptoms
Videler 2011 (56 participants) asked patients to report symptoms
on a 0 to 10 VAS (0 = no complaints, 10 = worst possible symp-
toms) for the following individual symptoms: headache, nasal ob-
struction, rhinorrhoea, post-nasal drip, feeling of fullness, smell
disturbance, facial pain, toothache, tears, coughing, nasal bleed-
ing and crusts. The paper presents the mean change from baseline
in the symptoms scores after treatment (12 weeks). However, the
results were very highly skewed and only the mean and SD were
reported. The study reported no statistically significant difference
using the Mann Whitney U test. We are uncertain whether there
was a difference at the end of the three-month treatment course
for any of the individual symptoms.
Nasal obstruction:mean change in azithromycin group -1.1 (SD
3.6); mean change in placebo group -1.4 (SD 2.9).
Rhinorrhoea:mean change in azithromycin group -0.7 (SD 3.1);
mean change in placebo group -0.7 (SD 2.2).
Facial pain: mean change in azithromycin group 0.7 (SD 3.3);
mean change in placebo group -0.6 (SD 2.5).
Loss of sense of smell: mean change in azithromycin group -0.4
(SD 3.5); mean change in placebo group -0.9 (SD 3.2).
None of the results for individual symptoms are presented in the
GRADE ’Summary of findings’ table as we did not consider this
to be a priority outcome.
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3. Significant adverse effect: gastrointestinal disturbances
Videler 2011 (56 participants) presented information on the num-
ber of people who reported “mild gastrointestinal complaints,
mostly mild diarrhoea”. The denominator is not clear for this out-
come and so we used the denominators at 12 weeks in the analysis.
There was no demonstrable difference in the rate of gastrointesti-
nal disturbances between the groups (RR 1.07, 95% CI 0.16 to
7.10; 56 participants; one study) (Analysis 2.2).
Secondary outcomes
1. General health-related quality of life
One study asked participants (56) to complete the SF-36 generic
quality of life measure before and after treatment (Videler 2011).
The paper presented a table of the calculated P values, comparing
the antibiotic group with the placebo group for the different do-
mains of the SF-36. The study authors noted that there were no
statistically significant results for any of the domains at 12 weeks
(end of treatment) or at 14 weeks (two weeks after the end of
treatment).
2. Other adverse event: skin suspected allergic reaction (rash
or skin irritation)
Videler 2011 stated that “No serious adverse events were reported
during the use of trial medication other than mild gastrointestinal
complaints...”. It is not clear whether skin irritation would have
been reported.
3. Other adverse event: anaphylaxis or other serious allergic
reactions such as Stevens-Johnson syndrome
Videler 2011 stated that “No serious adverse events were reported
during the use of trial medication other than mild gastrointesti-
nal complaints...”, so we assumed that if an anaphylaxis event or
other serious allergic reactions had occurred, this would have been
reported in the paper. As no events were reported in either arm no
risk estimate can be provided.
4. Endoscopic scores (including nasal polyps score)
Videler 2011 presented endoscopic score results. All patients un-
derwent endoscopy and the following elements were graded:
• mucosal colour (0 to 1) (left and right);
• mucosal swelling (0 to 2) (inferior and middle turbinate;
both sides);
• nasal secretions (0 to 1);
• crusts (0 to 2);
• polyps (0 to 2) (inferior, middle meatus and ethmoid area;
both sides); and
• postnasal drip (0 to 1).
The total range of final values was 0 to 25 (0 = least severe, 25
= most severe). The full results were not reported in the paper.
The paper stated that “one item showed a significant difference in
the chi-square test for trend. Secretion is the left middle meatus
improvedmore in the antibiotic group”. No significant differences
were found for any of the other items.
5. Computerised tomography (CT) scan score
This was not reported as an outcome.
Antibiotics versus intranasal corticosteroids
One study compared a systemic macrolide antibiotic (clar-
ithromycin) with intranasal steroids (mometasone furoate) in 43
Chinese people with chronic rhinosinusitis without nasal polyps
(Zeng 2011).
Primary outcomes
1. Disease-specific health-related quality of life
This was not reported as an outcome in the study.
2. Disease severity, as measured by patient-reported symptom
score
One study in people with chronic rhinosinusitis without nasal
polyps reported this outcome (Zeng 2011). The trial participants
(43) reported individual symptoms on a 0 to 10 visual analogue
scale (VAS) (0 = no complaints whatsoever, 10 = worst imagin-
able complaints) at baseline and at the end of the treatment (three
months). The following symptoms were included: nasal obstruc-
tion, headache, facial pain, loss of sense of smell and rhinorrhoea.
We added together the results for the four symptoms representing
the EPOS 2012 criteria (nasal obstruction, rhinorrhoea, loss of
sense of smell and facial pain) to create the mean total symptom
score (range 0 to 40, 0 = least complaints) in the antibiotics and
intranasal corticosteroids group (see Dealing with missing data
for the methods used on the results). It is very uncertain whether
there is a difference between the groups as patient-reported disease
severity was similar (MD -0.32, 95% CI -2.11 to 1.47; 43 partic-
ipants; one study) (Analysis 3.1). The observed mean difference
corresponds to a small effect size (SMD = 0.11).
Individual symptom scores
Zeng 2011 also provided the results for the individual symptom
scores measured as described above at the end of the three-month
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treatment course. The results are presented in Analysis 3.2 and
below.
Nasal obstruction:MD 0.34, 95% CI -0.79 to 1.47; 43 partici-
pants; one study.
Rhinorrhoea: MD 0.22, 95% CI -0.81 to 1.25; 43 participants;
one study.
Facial pain: MD -0.05, 95% CI -0.21 to 0.11; 43 participants;
one study.
Loss of sense of smell: MD -0.83, 95% CI -1.75 to 0.09; 43
participants; one study.
None of the results for individual symptoms are presented in the
GRADE ’Summary of findings’ table as we considered it to be re-
presenting information that was already included in the disease
severity score.
3. Significant adverse effect: gastrointestinal disturbances
Zeng 2011 did not mention adverse events.
Secondary outcomes
1. General health-related quality of life
This was not reported as an outcome.
2. Other adverse event: skin suspected allergic reaction (rash
or skin irritation)
Zeng 2011 did not mention adverse events.
3. Other adverse event: anaphylaxis or other serious allergic
reactions such as Stevens-Johnson syndrome
Zeng 2011 did not mention adverse events.
4. Endoscopic scores (including nasal polyps score)
One study (43 participants) reported this outcome for people with
chronic rhinosinusitis without nasal polyps (Zeng 2011). Endo-
scopic appearance was measured using the Lanza-Kennedy score,
which assesses discharge (0 to 2, 0 = no discharge) and swelling
(0 to 2, 0 = no swelling) on each side separately at the end of
treatment (three months). The scores from each side were then
added. The paper presents the results for discharge and swelling
separately.
Discharge: The discharge result at 12 weeks after dosing in the
antibiotics group was 0.32 ± 0.57 and for the intranasal steroids
group was 0.71 ± 1.23.
Swelling: The swelling result at 12 weeks after dosing in the an-
tibiotics group was 0.23 ± 0.61 and for the intranasal steroids
group was 0.62 ± 0.92.
Total score: The discharge and swelling scores were combined to
given the overall endoscopic score (range: 0 to 8; 0 = least severe).
One study (43 participants) gave results at 12 weeks after dosing
(MD -0.78, 95% CI -1.52 to -0.04; 43 participants; one study)
(Analysis 3.3). The observed mean difference corresponds to a
moderate effect size (SMD = 0.62).
We did not present endoscopy scores in the ’Summary of findings’
table as we did not consider it to be a priority outcome.
5. Computerised tomography (CT) scan score
This was not reported as an outcome.
Adverse events related to intranasal corticosteroids use
Adverse events relating to intranasal steroid use were identified
in Chong 2016a and Chong 2016b as epistaxis, local irritation
and osteoporosis. Zeng 2011 did not mention any adverse events
related to the use of intranasal steroids.
Antibiotics versus oral steroids
One study (28 participants) compared a tetracycline (doxycycline)
(duration approximately 20 days) with a 20-day course of oral
steroids (methylprednisolone) in adultswithmassive bilateral nasal
polyps or bilateral nasal polyps that had recurred after surgery (Van
Zele 2010).
Primary outcomes
1. Disease-specific health-related quality of life
This was not reported as an outcome.
2. Disease severity, as measured by patient-reported symptom
score
Van Zele 2010 (28 participants), in people with chronic rhinosi-
nusitis with nasal polyps, measured the following patient-assessed
symptoms: anterior rhinorrhoea, nasal obstruction, post-nasal drip
and loss of sense of smell after treatment (20 days) and 12 weeks
from the start of the trial. Details of the scales used to record symp-
toms are not provided in the paper and the results in the paper are
not sufficient to allow them to be used. We contacted the author
but they did not provide additional information.
3. Significant adverse effect: gastrointestinal disturbances
One study (28 participants), in people with chronic rhinosinusi-
tis with nasal polyps, reported the adverse event of “reflux and/
or gastric pain” at 12 weeks (Van Zele 2010). There were a low
number of events in both arms: 2/14 in the doxycycline arm and
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2/14 in the oral steroids arm (RR 1.00, 95% CI 0.16 to 6.14; 28
participants; one study) (Analysis 4.1).
Secondary outcomes
1. General health-related quality of life
This was not reported as an outcome.
2. Other adverse event: skin suspected allergic reaction (rash
or skin irritation)
One study (28 participants) in people with chronic rhinosinusitis
with nasal polyps reported the adverse event of “skin rash” at 12
weeks (Van Zele 2010). There were very few events in both arms:
2/14 in the doxycycline arm and 1/14 in the placebo arm (RR
2.00, 95% CI 0.20 to 19.62; 28 participants; one study) (Analysis
4.2).
3. Other adverse event: anaphylaxis or other serious allergic
reactions such as Stevens-Johnson syndrome
One study (28 participants) in people with chronic rhinosinusitis
with nasal polyps reported adverse events well and so we assumed
that if an anaphylaxis event or other serious allergic reaction had
occurred, this would have been reported in the paper (Van Zele
2010). No events were reported in either arm so no risk estimate
could be calculated.
4. Endoscopic scores (including nasal polyps score)
One study in people with chronic rhinosinusitis with nasal polyps
measured nasal polyps score on a five-point scale (0 to 4), which
was used for each nostril and then summed to get an overall nasal
polyp score (Van Zele 2010). The paper presented the results
graphically as change from baseline polyps score, however data
on the variance of the point estimates were not available for this
study and it was not possible to impute them from other studies
due to differences in the scale. It was therefore not included in the
analysis.
This outcome is not presented in the ’Summary of findings’ table
as we did not consider it to be a priority outcome.
5. Computerised tomography (CT) scan score
This was not reported as an outcome.
Adverse events related to oral steroid use
Adverse events related to oral steroid use were identified in the
Cochrane reviews Head 2016a and Head 2016b as mood dis-
turbances, insomnia and gastrointestinal disturbances. Of these,
gastrointestinal disturbances have already been reported (Analysis
4.1). Mood disturbances were not reported as an adverse event in
the study included in this section (Van Zele 2010). Insomnia was
reported in one study (28 participants) but there was only one
event reported in each arm (RR 1.00, 95% CI 0.07 to 14.45; 28
participants; one study).
26Systemic and topical antibiotics for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Systemic antibiotics plus saline irrigation and intranasal corticosteroids compared with placebo plus saline irrigation and intranasal corticosteroids for chronic rhinosinusitis
Patient or population: part icipants with chronic rhinosinusit is
Intervention: systemic ant ibiot ics (macrolide) plus saline irrigat ion and intranasal cort icosteroids
Comparison: placebo plus saline irrigat ion and intranasal cort icosteroids
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
Without systemic an-
tibiotics3
With systemic antibi-
otics3
Difference
Disease-specif ic HRQL
assessed with: SNOT-
22
Follow-up: 14 weeks
and 6 months
of part icipants: 53
(1 RCT)
The data were highly skewed. Median values were not presented in the paper. The paper reports no
stat ist ically signif icant dif f erences between the groups at any of the t ime points (P values < 0.05
using the Mann Whitney U-test)
⊕⊕©©
LOW1
It is unclear whether
there is an important dif -
ference between groups.
The data are dif f icult to
interpret because:
1) the baseline score
was higher in the an-
t ibiot ics groups, i.e.
worse (ant ibiot ics = 48.
2, placebo = 40.0);
2) the data were highly
skewed. Only the mean
and SD values were re-
ported, and these are not
good est imates of the
average change in pa-
t ients
Disease severity
assessed with: 5-
point ‘‘pat ient re-
sponse’’ scale and di-
chotomised into people
who improved versus
RR 1.50
(0.81 to 2.79)
345 per 1000 517 per 1000
(279 to 962)
172 more per 1000
(66 fewer to 617 more)
⊕©©©
VERY LOW2
The proport ion of pa-
t ients who improved
was potent ially slight ly
higher in the ant ibiot ics
group. However, there
were also pat ients who2
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people who remain un-
changed or had wors-
ened symptoms
Follow-up: 3 months
No of part icipants: 56
(1 RCT)
worsened
Gastrointest inal distur-
bances
Follow-up: 3 months
of part icipants: 56
(1 RCT)
RR 1.07
(0.16 to 7.10)
Study populat ion ⊕⊕©©
LOW1
It is very uncertain
whether there is a dif fer-
ence between the groups
69 per 1000 74 per 1000
(11 to 490)
5 more per 1000
(58 fewer to 421 more)
General health-related
quality of lif e
assessed with: SF-36
Follow-up: 3 months
of part icipants: 56
(1 RCT)
One study reported the SF-36 at the end of treatment (12 weeks) (n = 56) and 2 weeks af ter the end of treatment (14 weeks) (n = 53). The study
authors noted that there were no stat ist ically signif icant dif f erences for any of the SF-36 domains between the group receiving ant ibiot ic plus saline
irrigat ion and intranasal cort icosteroids and the group receiving placebo plus saline irrigat ion and intranasal cort icosteroids. No further information
is presented
Suspected allergic re-
act ion (rash or skin irri-
tat ion)
The study did not report this as an outcome.
Anaphylaxis or other
very serious react ions
(e.g. Stevens-Johnson
syndrome)
Follow-up: 3 months
of part icipants: 33
(1 RCT)
No events were reported in either arm. The ef fect size could not be est imated
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval;HRQL: health-related quality of lif e; M D: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; SM D: standardised mean dif ference; SNOT-
22: Sino-Nasal Outcome Test-22
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded to low quality: part icipants included in the trial had more severe, recalcit rant CRS compared with the average
CRS populat ion. The trial is very small (n = 53) and the results are imprecise.
2Downgraded to very low quality: part icipants included in the trial had more severe, recalcit rant CRS compared with the
average CRS populat ion. The trial is very small (n = 53), the results are imprecise and there is no information provided about
the validat ion of the rat ing scale.
3All pat ients in both study arms received nasal saline irrigat ion and most pat ients (70%) received intranasal cort icosteroids.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Systemic antibiotics compared with intranasal corticosteroids for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Intervention: systemic ant ibiot ics (macrolide)
Comparison: intranasal cort icosteroids
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
Without systemic an-
tibiotics
With systemic antibi-
otics
Difference
Disease-specif ic HRQL The study did not report this as an outcome
Disease severity, as
measured by pat ient-re-
ported symptom score
(0 to 40),
measured by combin-
ing 4 individual symp-
toms2
Follow-up: 3 months
of part icipants: 43
(1 RCT)
- The mean disease
severity score with-
out systemic ant ibi-
ot ics was 6
The mean disease
severity score in the in-
tervent ion group was 0.
32 lower (2.11 lower to
1.47 higher)
MD 0.32 lower
(2.11 lower to 1.47
higher)
⊕⊕©©
LOW1
Lower scores indicate less se-
vere symptoms (possible range
0 to 40)
It is very uncertain whether
there was a dif ference in dis-
ease severity (as measured by
combined symptoms score) be-
tween the groups. The mean
dif ference corresponds to a
small ef fect size (SMD 0.11)
Gastrointest inal distur-
bances
The study did not provide any information about adverse events
General health-related
quality of lif e
The study did not report this as an outcome
Suspected allergic re-
act ion (rash or skin irri-
tat ion)
The study did not provide any information about adverse events
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Anaphylaxis or other
very serious react ions
(e.g. Stevens-Johnson
syndrome)
The study did not provide any information about adverse events
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval;HRQL: health-related quality of lif e; M D: mean dif ference; RCT: randomised controlled trial; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded to low quality due to risk of bias due to study design (open-label study, lack of information about allocat ion
concealment) and small number of part icipants (n = 43) leading to imprecise results.
2Symptoms included in overall symptom score were: nasal obstruct ion, rhinorrhoea, loss of sense of smell and facial pain.
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Systemic antibiotics compared with oral corticosteroids for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Intervention: systemic ant ibiot ics (macrolide)
Comparison: oral cort icosteroids
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
Without systemic an-
tibiotics
With systemic antibi-
otics
Difference
Disease-specif ic HRQL The study did not report this as an outcome
Disease severity score The study did not report this as an outcome
Gastrointest inal distur-
bances
Follow-up: 3 months
of part icipants: 28
(1 RCT)
RR 1.00
(0.16 to 6.14)
Study populat ion ⊕©©©
VERY LOW1
It is very unclear whether
there is a dif ference
in gastrointest inal dis-
turbances between the
groups
143 per 1000 143 per 1000
(23 to 877)
0 fewer per 1000
(120 fewer to 734 more)
General health-related
quality of lif e
The study did not report this as an outcome
Suspected allergic re-
act ion (rash or skin irri-
tat ion)
Follow-up: 3 months
of part icipants: 28
(1 RCT)
RR 2.00
(0.20 to 19.62)
Study populat ion ⊕©©©
VERY LOW1
It is unclear whether
there is a dif ference in
skin irritat ion between
the groups
71 per 1000 143 per 1000
(14 to 1000)
71 more per 1000
(57 fewer to 1330 more)
Anaphylaxis or other
very serious react ions
(e.g. Stevens-Johnson
syndrome)
Follow-up: 3 months
No events were reported in either arm. The ef fect size could not be est imated
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of part icipants: 28
(1 RCT)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval;HRQL: health-related quality of lif e; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded to very low quality due to lim itat ions of study design (lack of information about randomisat ion, allocat ion
concealment and blinding, high risk of report ing bias), indirectness of the included populat ion and intervent ion (study
included a populat ion who were more severely af fected, those with recurrent polyps or recalcit rant disease, and the
intervent ion was a 20-day course of ant ibiot ics) and imprecision (small study, n = 28) with a low number of events leading
to large conf idence intervals.
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D I S C U S S I O N
Summary of main results
Five studies are included in this review, with a total of 293 ran-
domised participants. These studies provide evidence for four dif-
ferent comparisons. There was variation in the trials regarding the
type of antibiotics used, the duration of treatment, the concomi-
tant treatments and the outcomes measured.
Antibiotics versus placebo
Three studies compared antibiotic treatment with placebo (176
participants).
Disease-specific health-related quality of life (HRQL)was reported
using the SNOT-20 (0 to 5, 5 = worst quality of life) by one
study in adults without nasal polyps (64 participants). At the end
of treatment, the SNOT-20 score was lower in the group receiv-
ing three months of treatment with macrolide antibiotics than the
placebo group (mean difference (MD) -0.54 points, 95% confi-
dence interval (CI) -0.98 to -0.10). However, three months after
treatment it was uncertain whether there was a difference in effect
between the groups. We assessed the evidence to be of moderate
quality (GRADE).
One study in people with polyps (33 participants) provided in-
formation on gastrointestinal disturbances and suspected allergic
reaction (rash or skin irritation) 10 weeks after a short course of
tetracycline antibiotic treatment (duration ~20 days) compared
with placebo treatment. It was very uncertain whether there was
an increase in gastrointestinal disturbances in the antibiotics group
(risk ratio (RR) 1.36, 95% CI 0.22 to 8.50; very low quality evi-
dence) or skin irritation (RR 6.67, 95% CI 0.34 to 128.86; very
low quality evidence).
None of the studies presented information on patient-reported
disease severity or general health-related quality of life.
Antibiotics and saline irrigation versus placebo and
saline irrigation
One study (60 participants) compared a three-month treatment
course of macrolide antibiotic with placebo; all participants also
used nasal saline irrigation and 70% used intranasal corticos-
teroids. Disease-specific HRQL was reported using the SNOT-22
(0 to 110, 110 = worst quality of life). The data for this outcome
were highly skewed (medians not reported) and there was baseline
imbalance between the groups that could be of clinical impor-
tance. The data were difficult to interpret and it is unclear whether
there was an important difference between groups after treatment.
We assessed the quality of the evidence to be low. To assess patient-
reported disease severity the study authors asked participants to
measure the effect of the treatment course on a five-point scale
(-2 desperately worse to 2 cured) at the end of treatment (three
months). We dichotomised this to give a proportion of patients
who had improved (considering patients who scored “improve-
ment” and “cured” as improved). There was no difference between
the antibiotics and placebo groups; the risk ratio for improvement
in symptoms was 1.50 (95% CI 0.81 to 2.79; 56 participants;
one study) and there was also a slightly higher number of people
who felt worse after the treatment. We assessed the quality of the
evidence to be very low.
Therewas nodemonstrable difference in the rate of gastrointestinal
disturbances between the groups (RR 1.07, 95% CI 0.16 to 7.10).
General HRQL was measured using the SF-36 instrument. The
full results were not reported but the authors state that there was
no difference between the two groups at the end of treatment (12
weeks) or two weeks later.
Antibiotics versus intranasal steroids
One study (43 participants) compared a three-month treatment
course of macrolide antibiotic with intranasal corticosteroids in
people without polyps. Patient-reported disease severity was as-
sessed using a composite symptom score (range: 0 to 40; 0 = no
symptoms). It was very uncertain whether the effect of antibiotics
differed from intranasal steroids as patient-reported disease sever-
ity was similar (MD -0.32, 95% CI -2.11 to 1.47; low quality
evidence).
Antibiotics versus oral steroids (one study)
One study (28 participants) in people with nasal polyps compared
a short course of tetracycline antibiotic treatment (unclear dura-
tion, ~20 days) with a 20-day course of oral corticosteroids. We
were unable to extract data on any of the primary or secondary
efficacy outcomes from the paper. It was very uncertain whether
there was an increase in gastrointestinal disturbances (RR 1.00,
95% CI 0.16 to 6.14) or skin irritation (RR 2.00, 95% CI 0.20
to 19.62) as the results for these outcomes were similar in both
groups. We assessed this evidence to be of very low quality.
Overall completeness and applicability of
evidence
There were only five studies that met the inclusion criteria for
this review. All of these studies were small (43 to 79 participants)
and they covered four different comparisons. Other differences
between the studies include the following:
• Age of participants: four studies recruited adults (Van Zele
2010; Videler 2011; Wallwork 2006; Zeng 2011); one only
included children (Otten 1994).
• Nasal polyps: three studies only included people without
nasal polyps (Otten 1994; Wallwork 2006; Zeng 2011), one a
mix of people with and without nasal polyps where the results
were not presented separately (Videler 2011), and the last study
only included patients with nasal polyps (Van Zele 2010)
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• Antibiotics: each of the studies used different antibiotics.
Of these, three belonged to the macrolide class (roxithromycin
(Wallwork 2006), azithromycin (Videler 2011), clarithromycin
(Zeng 2011)), one was a tetracycline (doxycycline (Van Zele
2010)), and the last was a cephalosporin-type antibiotic (cefaclor
(Otten 1994)).
• Duration of antibiotics: whilst three studies investigated
longer courses of antibiotics for up to three months of treatment,
one study looked only at a short course (approximately 20 days),
but followed patients up for 10 weeks after the initial treatment
had ended (Van Zele 2010).
• Comparisons: three studies compared antibiotics against
placebo (Otten 1994; Van Zele 2010; Wallwork 2006), one
against intranasal steroids (Zeng 2011), and one against oral
steroids (Van Zele 2010). The remaining study used antibiotics
as an adjuvant, on top of nasal saline irrigation, and 70% of
participants also used intranasal corticosteroids (Videler 2011).
When the differences between the studies are considered, it is
difficult to drawoverall conclusions for this review.This underlines
the issues we encountered with the paucity of reporting of trial
data, as presented here.
The restriction of study inclusion only to those that had a mini-
mum duration of follow-up of three months may have had a big
impact on the evidence that we found to answer this review ques-
tion. We chose this cut-off point so that the results of the review
would reflect the impact of treatment on medium-term outcomes
in chronic rhinosinusitis patients. There were potentially 11 ad-
ditional studies where the follow-up period was between 4 and 12
weeks, although some of these studies may have been reporting
acute sinusitis. Although the inclusion of these studies may have
added to the evidence base, it should be remembered that chronic
rhinosinusitis is a chronic condition, the definition ofwhichmeans
that patients will have experienced symptoms for more than 12
weeks. Reviewing the evidence for the effects of interventions in
people who have been followed up for less than 12weeks could po-
tentially be misleading with regard to the long-term consequences
of treatment and whether any benefits are sustained: it would re-
flect a shorter-term view of the impact of treatment. However, this
is an issue that could be considered in future updates of the review.
Adverse events were generally poorly reported in the studies. Of
the five studies included, three did not mention adverse events
(Otten 1994; Wallwork 2006; Zeng 2011). The remaining two
presented results for adverse events but did not provide details of
how the events were defined or the methods of collection (Van
Zele 2010; Videler 2011). None of the studies were powered to
identify adverse events such as allergic reactions and so it is not
surprising that no such events were reported. Caution should be
applied when interpreting the adverse events results as this does
not mean that there is no difference between the two groups.
In addition, none of the studies were set up to investigate other
important factors related to the extended use of antibiotics, such
as shifts in bacterial flora and increase in subsequently induced
bacterial resistance.
Elevated serum immunoglobulin (IgE) levels are seen in patients
with atopic disease. It has been suggested that IgE might be a sur-
rogate for an eosinophilic subgroup of chronic rhinosinusitis and
thus a non-responder to the anti-neutrophilic effects of macrolides
(Harvey 2009). Patients with eosinophilic disease have previously
been noted to be poor responders (Haruna 2009). One included
study showed a significant improvement in the endoscopic score
and the SNOT-20 score at the end of treatment (12 weeks) in
those patients with a low serum-IgE (Wallwork 2006). However,
this has not been corroborated by other studies. Zeng 2011 did
not find an influence of atopy on the therapeutic effect of clar-
ithromycin and so this factor clearly requires further investigation.
Quality of the evidence
With the exception of the evidence for health-related quality of life
in the comparison of antibiotics with placebo (which we assessed
to be of moderate quality), the quality of the evidence for all of
the other outcomes assessed was low or very low, including for the
adverse events outcomes that were reported.
The quality of the evidence was affected by a number of issues:
methodological limitations, the lack of validation of outcome in-
struments, the directness of the population included and the sam-
ple sizes of the studies. Some of the studies were poorly reported
and lacked information about randomisation, allocation conceal-
ment and blinding. Where the results for disease-specific quality of
life were presented the studies had generally used validated instru-
ments. However, for the other patient-reported outcomes, specifi-
cally symptom severity scores, the studies did not provide informa-
tion on instrument validation. The variety of chronic rhinosinusi-
tis populations included in the studies was wide and it is unclear
how the results of studies in participants with nasal polyps that
have recurred after surgery (Van Zele 2010), or the results from
a population without nasal polyps who have never had surgery
(Zeng 2011), can be applied to the general chronic rhinosinusitis
population.
Lastly, the size of the studies, and consequently the precision of
the results, was one of the biggest factors affecting study quality.
The average size of the studies included in this review was 59
participants in total. This limits how much confidence can be
placed in the results.
Potential biases in the review process
At the protocol stage we identified the validation of outcome mea-
sures as a potential bias that could affect the validity of the results
(Chong 2015). Many of the studies did not use patient-reported
symptom scales that had been appropriately validated. The lack
of validated scores meant that we were required to make judge-
ments based on the face validity of the scale, rather than having
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reliable validity data. Even where validated scales had been used
these may have missed elements that are key to the quality of life
of people with chronic rhinosinusitis. For example, the SNOT-
20 questionnaire omits nasal blockage and smell function (which
are included in the SNOT-22 instrument). As validated disease-
specific questionnaires exist, future trials would benefit from using
these as primary outcome measures. Recent preliminary work in
the UK has underlined this and identified the need to establish a
core outcome set for rhinosinusitis (Hopkins 2016).
Due to the lack of outcomes reported using validated measures,
in order to enable some comparison between studies we took the
decision to combine the scores for individual symptoms to create
a total symptom score. The methods we used to do this are de-
scribed in the methods section (Dealing with missing data). The
symptoms included were based on the EPOS 2012 diagnostic cri-
teria, but the score calculated was not a validated measure and
the correlation between symptoms was not accounted for in the
results. This may have had an effect on themagnitude of the effect
size.
Agreements and disagreements with other
studies or reviews
The current review updates a previous Cochrane review (
Piromchai 2011). It increases the scope of the review to include
both adults and children, patients both with and without nasal
polyps, and both systemic and topical antibiotics. The previous
Cochrane review included one study (Wallwork 2006), which is
also included in this review. Two studies included in this review
were published after the publication date of the previous review
(Videler 2011; Zeng 2011). Two additional studies have been in-
cluded due to the population inclusion criteria being widened to
include children (Otten 1994), and people with nasal polyps (Van
Zele 2010). Despite the inclusion of additional trials the conclu-
sion regarding the lack of evidence for this intervention is still
valid.
The EPOS 2012 guidelines separated the evidence into those with
and those without nasal polyps, and then each category into three
sections: short-term systemic antibiotics (less than four weeks),
long-term systemic antibiotics and topical antibiotics.
For patients with nasal polyps, EPOS 2012 identified two stud-
ies investigating short-term antibiotics (Schalek 2009; Van Zele
2010). We included Van Zele 2010 in this review but we excluded
Schalek 2009 as all of the patients in the study underwent func-
tional endoscopic sinus surgery (FESS) during the trial. They con-
cluded that there may have been a small improvement in polyp
size and postnasal discharge but that the evidence for improved
quality of life was lacking. For people with chronic rhinosinusitis
with nasal polyps, the EPOS 2012 document included three pa-
pers for long-term antibiotics, all of which were open studies that
we excluded from this review due to the study design. They con-
cluded that there may have been an improvement in patient symp-
toms and polyp size with antibiotics but that the clinical benefits
had not been fully investigated. There were no studies identified
that investigated topical antibiotics in patients with nasal polyps,
which met the inclusion criteria.
For patients without nasal polyps, EPOS 2012 identified three
studies that investigated short-term use of antibiotics (Huck 1993;
Legent 1994;Namyslowski 1998), all of which compared different
antibiotics (not placebo-controlled) and that we excluded from
this review as the follow-up duration was less than three months.
Their conclusion was that short-term use was probably only rele-
vant for exacerbations with a positive culture. For long-term an-
tibiotics, the EPOS 2012 document reviewed the evidence for the
use of macrolides in lower airway populations (diffuse panbron-
chiolitis and cystic fibrosis). They also identified two randomised
controlled trials (Videler 2011; Wallwork 2006), both of which
we included in this review, and seven open studies in the chronic
rhinosinusitis population, which we excluded due to study design.
The report concluded that “long-term antibiotic treatment should
be reserved for patients where nasal corticosteroids and saline ir-
rigation has failed to reduce symptoms to an acceptable level”.
For topical antibiotics, the EPOS 2012 document identified three
placebo-controlled trials. We excluded all three from this review,
two due to the follow-up period (Desrosiers 2001; Sykes 1986),
and one because the timing of the outcome assessment was unclear,
although it was likely to be less than 12 weeks (Videler 2008).
They concluded that topical antibacterial therapy could not be
recommended in the treatment of chronic rhinosinusitis.
We identified one further well-conducted, recent systematic re-
view of macrolide therapy for chronic rhinosinusitis (Pynnonen
2013). This review found three studies, two of which we also in-
cluded in our review (Videler 2011; Wallwork 2006), and one
study that we excluded due to the duration of follow-up (three-
week treatment with eight-week follow-up) (Amini 2009). This
review analysed all three studies together, despite differences in the
background treatment (both participant groups receiving saline
and intranasal corticosteroids inVideler 2011), but concluded that
no clinically significant difference in patient-orientated outcomes
could be identified. However, they did raise the potential for there
being a subgroup of patients that may respond better (those with
low serum IgE) and suggested this as an aspect that merited more
research.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found very little evidence that systemic antibiotics are effec-
tive in patients with chronic rhinosinusitis. We did find moder-
ate quality evidence of a modest improvement in disease-specific
quality of life in patients with chronic rhinosinusitis without nasal
polyps receiving three months of a macrolide antibiotic. However,
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this improvement was small (0.5 points on a five-point scale) and
only seen at the end of the three-month course of treatment; by
three months later no effect was found.
It is unclear whether or not patients benefit from the use of an-
tibiotics when they are also using saline irrigation and intranasal
corticosteroids; the quality of this evidence is very low.
Despite a general understanding that the use of antibiotics can be
associated with adverse effects, including gastrointestinal distur-
bance, the results for adverse events in this review were very un-
certain as the number of participants in all the studies was small
and few events were reported.
We found no studies of topical antibiotics that met the inclusion
criteria.
Implications for research
The evidence (up to September 2015) for antibiotics in people in
chronic rhinosinusitis is of low quality, as we are uncertain about
the estimates. The evidence suggests that antibiotic treatment for
patients who have chronic rhinosinusitis may be beneficial in re-
ducing the size of the polyps, but that although symptoms may
be reduced in the short term compared to placebo this may not
be sustained. The evidence is from very small studies (fewer than
80 patients each), with a variety of populations, interventions and
comparisons. There are no well-reported data on adverse effects
or longer-term outcomes, which are important to provide infor-
mation on whether there is sustained benefit.
Future studies should be designed as adequately powered, dou-
ble-blind, randomised controlled trials and include patients with
chronic rhinosinusitis diagnosed using the EPOS 2012 criteria.
Trials should include both patients with and without nasal polyps
(with stratification by subgroup). This should include patients
whose symptoms have been refractory to treatment with saline
irrigation and intranasal steroids for at least three months.
With regard to the intervention, the macrolide class of antibiotics
is likely to yield the greatest benefit because these antibiotics have
both anti-inflammatory and antimicrobial properties, as demon-
strated in other respiratory tract disorders (Donath 2013; Shi
2014), and they should provide good coverage of typical chronic
rhinosinusitis flora (Genoway 2011). A number of publications
have, however, raised concerns about cardiac toxicity with ery-
thromycin in patients with a prolonged QT interval, and the most
recent evidence has also implicated clarithromycin (Iyer 2016).
However, in a chronic rhinosinusitis population, clarithromycin
has a reasonable side effect profile, as seen in a recent feasibility
study (Bewick 2014). There is still a case for placebo as the first
choice of comparator as the evidence for the efficacy of antibiotics
compared to placebo is not conclusive; however, surgical interven-
tion may not be an unreasonable alternative comparator. Atten-
tion should be paid to any concurrent treatments given and these
should be decided at the protocol stage.
The primary outcomes should be relevant to patients and any
disease-specific instruments should be validated in people with
chronic rhinosinusitis. The methods for defining and recording
adverse events should be considered at the protocol stage and
the adverse events recorded should include gastrointestinal distur-
bances, skin rashes, dysgeusia, hepatoxicity and insomnia. The age
of patients should be taken into account. Endoscopic evaluation
should not be chosen as a primary outcome because the correlation
between endoscopic results and patient symptoms is unclear. All
outcomes should be reported at longer-term follow-up (a mini-
mum of three months and ideally six months). Much longer-term
time points should also be considered (between six months and
five years) (Soler 2010).
This review is one of a suite of reviews of medical treatments for
chronic rhinosinusitis, each of which features its own research rec-
ommendations. Across all reviews, key features of future research
are as follows:
• Trials should be adequately powered and imbalances in
prognostic factors (for example, prior sinus surgery) must be
accounted for in the statistical analysis.
• Study participants should be diagnosed with chronic
rhinosinusitis using the EPOS 2012 criteria and should
primarily be recruited based on their symptoms. Different
patient phenotypes (that is, those with and without nasal polyps)
should be recognised and trials should use stratified
randomisation within these subgroups or focus on one or other
of the phenotypes.
• Studies should focus on outcomes that are important to
patients and use validated instruments to measure these.
Validated chronic rhinosinusitis-specific health-related quality of
life questionnaires exist, for example the Sino-Nasal Outcome
Test-22 (SNOT-22). Patients may find dichotomised outcomes
easiest to interpret; for example the percentage of patients
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
The development of a standardised set of outcomes, or core
outcome set, for chronic rhinosinusitis, agreed by researchers,
clinicians and patients, will facilitate this process.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Otten 1994
Methods 2-arm, double-blind, parallel-group RCT, with 1 week of treatment and follow-up at 6
to 12 weeks
Participants Location: the Netherlands
Setting of recruitment and treatment: 4 different ENT practices
Sample size:
Number randomised: 79 patients
Number completed: 75 patients: 37 in intervention, 38 in comparison
Participant (baseline) characteristics:
• Age range: 2 to 12 years, median 5 years
• Gender M/F: 39/36
• Main diagnosis: children with chronic sinusitis
• Polyps status: 0%
• Previous sinus surgery status: not stated
• Other important effect modifiers: none stated
Inclusion criteria:
Purulent rhinitis of 3months ormore duration; pus shown in themiddle nasal meatus by
anterior rhinoscopy; sinus radiograph showing 1 of the following: a) bilateral complete
opacity; b) bilateral mucosal swelling; c) unilateral mucosal swelling with unilateral
opacity; d) unilateral mucosal swelling or unilateral opacity
Exclusion criteria:
Allergic to cephalosporin, anatomical lesion of the ear, nose and throat such as a severe
septal deformation, a cleft palate or nasal polyps, previous treatment with antibiotics
within 3 weeks of the start of this trial, and general contra-indications such as cystic
fibrosis or suffering from cardiac, renal, hepatic or other serious diseases
Interventions Intervention (n = 37): cefaclor at a dose of 20 mg/kg/day divided into 3 equal doses for
1 week
Comparator group (n = 38): placebo for 1 week
Use of additional interventions (common to both treatment arms):
All participants received aspiration of sinus contents or antral washout (+ culturing of
contents) and antroscopy prior to starting intervention
Based on history, examination and sinus radiographs at 6 and 12 weeks, a sinus washout
with antroscopy was carried out in participants who had persistent sinusitis at 6 or 12
weeks (or both)
Outcomes No primary or secondary outcomes, as defined by the Cochrane review, were reported
Other outcomes reported by the study:
• “Complete resolution of sinusitis” at 6 weeks
• Sinus radiographs
• Microbiology
Funding sources No information provided
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Otten 1994 (Continued)
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This was a randomised double-
blind study”
Comment: nodetails on themethodof ran-
dom sequence generation
Allocation concealment (selection bias) Unclear risk Nodetails on themethod of allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “…placebo…”, “double-blind
study”
Comment: no further information on the
placebo to assess blinding effectiveness
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “…placebo…”, “double-blind
study”
Comment: no information provided re-
garding whether the healthcare profession-
als completing the outcome measurements
were blind to the treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One patient was withdrawn by
his parents, one failed to have sinus radio-
graphs, and two patients were withdrawn
because a third consultation demonstrated
a recurrent maxillary sinusitis that had ini-
tially resolved at the 6-week consultation.”
Comment: 4/79 (5%) patients were not
analysed, with reasons for exclusion stated,
however it is not clear at what point the
losses occurred
Selective reporting (reporting bias) Unclear risk The results are not well presented. No out-
comes of interest relevant to the Cochrane
review were reported in the paper. It is un-
clear whether adverse events were reported
We found no protocol for this study.
Other bias Unclear risk The paper did not provide a definition of
“sinusitis resolved”
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Van Zele 2010
Methods 3-arm, double-blind, multicentre, parallel-group RCT, with 20 days duration of treat-
ment and 12 weeks duration of follow-up
Participants Location: 5 sites in Belgium, Germany, Holland and Australia
Setting of recruitment and treatment: not given
Sample size: 47
Number randomised: 14 in antibiotics, 14 in oral steroids, 19 in placebo
Number completed: 14 in antibiotics, 14 in oral steroids, 12 in placebo
Participant (baseline) characteristics:
• Mean age years (SEM): antibiotics: 55.04 (4.28); oral steroids: 48.89 (3.23);
placebo: 54.67 (3.07)
• Gender (M/F): antibiotics: 11/3; oral steroids: 12/2; placebo: 15/4
• Main diagnosis: recurrent bilateral nasal polyps after surgery or massive bilateral
nasal polyps (grade 3 or 4)
• Polyps status: 100% with polyps
• Mean total polyp score (SEM): antibiotics: 5.93 (0.37); oral steroids: 5.86 (0.27);
placebo: 6.16 (0.29)
• Previous sinus surgery status: 100% with previous surgery
• Previous courses of steroids: no information
Other important effect modifiers:
• Allergy (%): antibiotics: 2 (14.3); oral steroids: 5 (35.7); placebo: 11 (57.9)
• Asthma (%): antibiotics: 4 (28.6); oral steroids: 6 (42.9); placebo: 5 (26.3)
• Aspirin intolerance (%): antibiotics: 1 (7.1); oral steroids: 2 (14.3); placebo: 5
(26.3)
Inclusion criteria:
Participants must be at least 18 years with a diagnosis of bilateral nasal polyps at screening
and baseline, which have recurred after surgical resection or nasal polyps that are grades
3 or 4 in both nares using the polyp scoring system
Women of childbearing potential must use a medically acceptable form of birth control
as defined by the study. Male participants must agree to use an adequate form of birth
control for the duration of the study as defined by the study
Participants with concurrent asthma must be maintained on no more than 1000 µg/d
beclomethasone dipropionate or the equivalent
Nasal polyp score: 0 = no polyp; 1 = small polyps in the middle meatus not reaching
below the inferior border of the middle concha; 2 = polyps reaching below the lower
border of the middle turbinate; 3 = large polyps reaching the lower border of the inferior
turbinate or polypsmedial to themiddle concha; 4 = large polyps causing almost complete
congestion/obstruction of the inferior meatus
Exclusion criteria:
The following are the exclusion criteria of the study: pregnancy, breastfeeding or pre-
menarcheal; oral corticosteroids within the 3 months before screening; systemic fungoid
infections; known allergic reaction tomethylprednisolone or tetracyclines; hypertension;
diabetes (type 1 and 2); glaucoma; tuberculosis; herpes infection; zona ophthalmica;
antineutrophil cytoplasmic antibodies such as Wegener’s granulomatosis, Churg-Strauss
syndrome and microscopic polyangiitis
Participants with acute sinusitis or concurrent nasal infection or participants who have
had a nasal or upper respiratory tract infection within 2weeks of the screening visit; cystic
fibrosis, primary ciliary dysfunction or Kartagener syndrome by history; those diagnosed
with a parasitic infection; HIV-positive or positive to hepatitis B surface antigen or C
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Van Zele 2010 (Continued)
antibodies
Participants must not have had an acute asthmatic attack requiring admission to a hos-
pital (excluding emergency department visits that resulted in direct discharge without
hospitalisation) within the 4 weeks before screening
Participants must not have received immunotherapy within the previous 3 months
Interventions Antibiotics (n = 14): doxycycline, oral, dose and frequency based on package informa-
tion and evidence of tissue penetration
Oral steroids (n = 14): oral methylprednisolone (32 mg/d on days 1 to 5; 16 mg/d on
days 1 to 5; 8 mg/d on days 11 to 20)
Placebo (n = 19): placebo, unlabelled lactose capsules, 20 days
Use of additional interventions (common to all treatment arms): systemic or local
corticosteroids or antibiotics were not allowed; if necessary nasal corticosteroids were
permitted as rescue medication 2 months after dosing with the study medication
Outcomes Primary outcomes:
1. Disease severity, measured by patient-assessed symptoms (anterior rhinorrhoea,
nasal obstruction, post-nasal drip and loss of sense of smell) at 20 days and 12 weeks.
Details of the scales used to record symptoms are not provided in the paper.
2. Significant adverse effect: gastrointestinal disturbances
Secondary outcomes:
1. Polyps size measured by endoscopic appearance using a scale as presented in the
inclusion criteria
2. Other adverse effects: skin irritation
3. Other adverse effects: anaphylaxis or other serious allergic reactions such as
Stevens-Johnson syndrome
Other outcomes reported by the study:
• Nasal peak inspiratory flow
• Blood analysis for eosinophils, eosinophilic cationic protein and soluble IL-5
receptor α
• Nasal secretion analysis for eosinophilic cationic protein, IL-5, IgE, matrix
metalloprotease-9, myeloperoxidase
• Need for rescue surgery and need for rescue nasal steroids
Funding sources “Supported by a grant from the Flemish Scientific Research Board, FWO Nr. A12/5-
HBKH3 (holder of a Fundamenteel KlinischMandaat), by a postdoctoral grant from the
Research Foundation Flanders (FWO), and by postdoctoral mandate from the Research
Foundation Flanders (FWO).”
Declarations of interest “Disclosure of potential conflict of interest: P. J. Wormald has received royalties from
Medtronic ENT, is a consultant for NeilMed, and has received research support from
the Garnett Passe and Rodney Williams Foundation. W. Fokkens has received research
support from GlaxoSmithKline and Stallergenes. A. Beule has received research support
from the European Union. The rest of the authors have declared that they have no
conflict of interest.”
Notes The paper presented 2 comparisons of interest for this review:
1) Antibiotics (doxycycline) versus placebo
2) Antibiotics (doxycycline) versus short-course oral steroids
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Van Zele 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were randomly
assigned to 3 groups by individuals not in-
volved in the study.”
Comment: pg 1070, col 1, para 3. No in-
formation was provided about how the se-
quence was generated. The number of pa-
tients randomised was small and there is a
risk the allocation between groups was not
balanced (14 versus 19)
Allocation concealment (selection bias) Unclear risk Quote: “… patients were randomly as-
signed to 3 groups by individuals not in-
volved in the study”
Comment: pg 1070, col 1, para 3
There is no information about allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “…double-blind…”, “...Placebo
(lactose) in unlabelled capsules”
Comment: pg 1069, abstract: methods, pg
1070 methods
Details of blinding are not clear within the
paper and it does not detail whether the oral
steroids and antibiotic medications were
given on the same dosing schedule andwere
in an identical form
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Study participants and personnel
were blind during the duration of the study.
Randomisation codes were revealed to re-
searchers after recruitment, data collection,
and data entry”
Comment: details of blinding are not clear
within the paper and it is not clear whether
the oral steroids and antibiotic medications
were given on the same dosing schedule
and were in an identical form, which could
compromise blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 7/47 patients dropped out of
the study (14.9%) but all were from the
placebo group 7/19 (36.8%). This is an im-
balance in drop-out rate and the reasons
for drop-out include “unsatisfactory ther-
apeutic effects”, “withdrawal of consent”
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Van Zele 2010 (Continued)
and “serious adverse events (asthma attack)
”. Patients who dropped out were still in-
cluded in the analysis using the last ob-
served carried forward. This may have had
an effect on the overall results and no sen-
sitivity analysis appears to have been com-
pleted to identify the impact
Selective reporting (reporting bias) Unclear risk Comment: all outcomes in the methods
section were reported in the full paper,
although many of them were presented
graphically, without providing values at key
time points. The data were not reported in
a way that allowed inclusion in the meta-
analysis for the review
The protocol document was available
(NCT00480298) and the outcomes appear
to be consistent between the protocol and
the paper.
Adverse events were reported but no meth-
ods were provided for their collection
Other bias Unclear risk Comment: details of the scales used tomea-
sure symptoms were not provided in the
paper and there is no information on val-
idation of any of the outcomes of interest
to this review
There was an imbalance in the number
of participants with “allergy” (oral steroids:
35.7%; placebo: 57.9%; antibiotics: 14.
3%) and “aspirin intolerant” (oral steroids:
14.3%; placebo: 26.3%; antibiotics: 7.1%)
in the baseline characteristics. There was
not a statistical difference between the
groups due to the study size being small.
A sensitivity analysis was completed by the
study authors to determine the number of
aspirin-intolerant patients affecting the re-
sults
Videler 2011
Methods 2-arm, double-blind, multicentre, parallel-group RCT, with 12 weeks duration of treat-
ment and 24 weeks duration of follow-up
Participants Location: 6 centres: Amsterdam, Helsinki, Leuven, London, Tampere and Zagreb
Setting of recruitment and treatment: tertiary referral centres
Sample size: 60
Number randomised: 29 in azithromycin (AZM), 31 in placebo
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Videler 2011 (Continued)
Number completed: 26 azithromycin (AZM), 27 in placebo
Participant (baseline) characteristics:
• Age: 20 to 70 years (medium = 49)
• Gender (male/female): AZM: 17/12; placebo: 13/18
• Main diagnosis: “recalcitrant CRS with and without nasal polyps”
• Polyps status: AZM: 18 (62.1%); placebo: 13 (41.9%). Note: polyps > grade 2
was an exclusion criterion (no scale given))
• Previous sinus surgery status: 55 patients (92%) had undergone ESS (surgery had
to be > 6 months before the start of the trial)
• Mean number of endoscopic sinus surgeries per patient: AZM: 1.8; placebo: 3.1
Other important effect modifiers:
• Asthma: AZM: 15; placebo: 15
• Positive skin pricks: AZM: 14; placebo: 15
Inclusion criteria:
• Diagnosis of moderate/severe chronic rhinosinusitis (according to the EPOS
definition)
• Age ≥ 18 and ≤ 70 years
• Absence of response to standard treatment regimes such as saline irrigation,
intranasal corticosteroids (> 6 weeks), short courses of antimicrobials (< 2 weeks) or
endoscopic sinus surgery. After treatment, patients returned to the outpatient clinic
with subjective complaints, objectified with signs at nasal endoscopy.
• Participants had to be > 6 months beyond the last surgical procedure on the nose
and sinuses, when performed.
• Sinus CT scan score ≥ 5 on the worst side (partial or total opacification)
according to the Lund-Mackay scoring system. CT scan had to be performed within 6
months before randomisation. If participants had undergone infundibulotomy and the
infundibulum was open on the worst side, a score of ≥ 3 was required.
• Willing to give informed consent and to adhere to visit schedules and medication
restrictions
• Adequate contraceptive precautions in participants with child-bearing potential
Exclusion criteria:
• Massive polyp (over grade 2)
• Hypersensitivity to macrolides
• Use of systemic antibiotics or systemic corticosteroids (or both) in 4 weeks before
start of study
• Other (including cystic fibrosis, congenital mucociliary problems, systemic
vasculitis or granulomatous disease, HIV or AIDS, severe septal deviation, craniofacial
malformations)
Interventions Intervention (n = 29): oral azithromycin (AZM), 500 mg per day for 3 days, then 500
mg per week for 11 weeks
Comparator group (n = 31): placebo with same amount, frequency and appearance as
the AZM group
Use of additional interventions: nasal saline irrigation twice daily (no details provided
of the solution used)
Intranasal or pulmonary steroids were allowed as long as the dosage was kept constant
throughout study participation (a maximum of 2 times the regular dose was accepted
(AZM: 19 (65.5%); placebo: 23 (64.5%))
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Videler 2011 (Continued)
Outcomes Primary outcomes:
1. Health-related quality of life, disease-specific: SNOT-22 score (range: 0 to 110),
measured at 14 and 24 weeks
2. Disease severity symptom score - symptoms (headache, nasal obstruction,
rhinorrhoea, post-nasal drip, feeling of fullness, smell disturbance, facial pain,
toothache, tears, coughing, nasal bleeding, crusts) each scored on a VAS from 0 to 10.
(In addition, some scores were also recorded for general symptoms (general health,
fatigue) on a VAS from 0 to 10). Measured at 14 weeks and 24 weeks. Also reported
that a “Patient Response Rating Scale” was used to classify the subjective effect of the
course (-2: desperately worse (deterioration of symptoms with significant impact on
normal life); -1: worse (compared with the pretreatment situation); 0: no change; 1:
improvement (although symptoms are present, they are scarcely troublesome); and 2:
cured (virtually no symptoms present))
3. Significant adverse effect: gastrointestinal disturbance
Secondary outcomes:
• Health-related quality of life, generic: using SF-36
• Endoscopy (polyps size or overall score): scoring system used that graded mucosal
colour (0 to 1), swelling (0 to 2), nasal secretions (0 to 1), polyps (0 to 2), postnasal
drip (0 to 1) and crusts (0 to 2). (Composite score: range uncertain - results section
refers to 25 items)
Other outcomes reported by the study:
• Patient Response Rating Scale (range -2 to +2)
• Peak nasal inspiratory flow (PNIF)
• Olfactory function using Sniffin’ Sticks odour identification screening test: range
0 to 12
• Endoscopically guided middle meatus culture
Funding sources “The azithromycin and placebo used in this study was kindly provided by PLIVA
HRVATSKA d.o.o., Zagreb, Croatia.”
Declarations of interest “None”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomized, numbered study
medication was kindly provided by phar-
maceutical company. Study medication
was allocated per centre in two randomised
blocks, containing 6 packs of treatment
each. Qualified subjects were given study
medication with consecutive numbering”
Allocation concealment (selection bias) Low risk Quote: “Randomized, numbered study
medication was kindly provided by phar-
maceutical company. Study medication
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Videler 2011 (Continued)
was allocated per centre in two randomised
blocks, containing 6 packs of treatment
each. Qualified subjects were given study
medication with consecutive numbering”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”, “The placebo arm
received the same amount of tablets, iden-
tical in appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: the outcomes were either pa-
tient-reported or were assessed by the in-
vestigators who were blinded to the treat-
ment allocation; assessed to have low risk
of detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 9/60 (15%) participants did not complete
the study. Reasons for non-completion are
given and are distributed between the in-
tervention and placebo group
No denominator given for each group at
the final time point (telephone conference
at 24weeks). Therewere 2participantswho
dropped out but the distribution between
groups is not clear
In addition, the denominator for measur-
ing adverse events (gastrointestinal distur-
bances) is not reported in the paper
Selective reporting (reporting bias) Unclear risk Some items were not reported in full in the
paper. Only partial data for the outcomes
of SF-36 and endoscopic score were pre-
sented, making presentation of numerical
results difficult
The method for collecting adverse events
was not presented in the paper
Protocol found: EUCTR-2005-001062-
14. The protocol did not mention the use
of the patient response scale. The protocol
states an aim to recruit 120 participants; 60
were actually recruited
Other bias Low risk SNOT-22 and SF-36 are validated out-
come measures. The validation of instru-
ments used to measure symptom severity
(0 to 10 VAS) and endoscopic scores was
not clear from the paper
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Wallwork 2006
Methods 2-arm, double-blind, parallel-group RCT, with a 12-week duration of treatment and 24-
week duration of follow-up
Participants Location: Australia, 2 sites
Setting of recruitment and treatment: hospital ENT department
Sample size: 64
Number randomised: 29 in intervention, 35 in comparison
Number completed: 26 in intervention, 30 in comparison
Participant (baseline) characteristics:
No specific information provided in the paper, other than that there was no difference
between the 2 treatment groups for age and gender. No information or previous surgery
• Main diagnosis: adults with a history consistent with a diagnosis of chronic
rhinosinusitis as outlined by the Rhinosinusitis Task Force
• Polyps status: 0% with polyps
Inclusion criteria: aged over 18 years. ACT scanwas performed to confirm the diagnosis
and was scored using the Lund-Mackay CT scoring system (baseline scores not provided
in the paper)
Exclusion criteria: history of cystic fibrosis, primary ciliary dyskinesia, immune defi-
ciency, allergic fungal sinusitis, nasal polyposis, and impairment of liver or renal func-
tion. Pregnant and breastfeeding women. Those taking medication with a known adverse
interaction with macrolides or with a history of macrolide hypersensitivity. Used topical
or systemic corticosteroids within 4 weeks of entering the study
Interventions Intervention (n = 29): roxithromycin tablet, 150 mg daily for 3 months
Comparator group (n = 35): placebo tablet daily for 3 months
Use of additional interventions (common to both treatment arms): none listed
Outcomes Primary outcomes
1. Health-related quality of life, disease-specific measured using Sinonasal Outcome
Test-20 (SNOT-20), pre-treatment, at 12 weeks immediately after treatment and at 24
weeks (12 weeks post-treatment)
Secondary outcomes
1. Endoscopy, scoring was carried out according to a template that graded swelling
(0 to 2), mucosal colour (0 to 1), polyps in the middle meatus (0 to 1) and nasal
secretions (0 to 3). Measurements were made pre-treatment and immediately after
treatment (12 weeks).
Other outcomes reported by the study:
• Patient response scale - patient-reported overall indication of their response to
treatment on a 6-point linear rating scale (1 to 6)
• Peak nasal inspiratory flow
• Saccharine transit time
• Olfactory function
• Nasal lavage (assays performed for interleukin-8, a2-macroglobulin and fucose)
Funding sources No information provided
Declarations of interest No information provided
Notes -
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Wallwork 2006 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…subjects were randomized by
the pharmacy department, using a random
number table…”
Comment: pg 190, col 1, para 2
Allocation concealment (selection bias) Unclear risk Comment: there is no specific information
about allocation concealment in the paper
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “…Patients and investigators were
kept blinded to the randomisation until the
completion of the study”
Comment: pg 190, col 1, para 2
Placebo tablets were used in the control
group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “…Patients and investigators were
kept blinded to the randomisation until the
completion of the study”
Comment: pg 190, col 1, para 2
As the disease-specific health-related qual-
ity of life score (SNOT-20) is patient-re-
ported it is expected that there will be a
low risk of bias if patients did not know
the group to which they were randomised.
The endoscopy score was assessed by the
primary author of the study and as the ’in-
vestigators’ were blinded to treatment allo-
cation, this is also assessed to be a low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 5/64 patients (7.8%) did not
complete treatment. Reasons are provided
in the paper. A further 3 patients did not
complete the 12-week post-treatment fol-
low-up, which results in a total of 8/64 (12.
5%). The paper reports that an intention-
to-treat analysis was completed
Selective reporting (reporting bias) Unclear risk Outcomes as listed in the methods section
were reported in the main text
Adverse events do not appear to have been
recorded
No protocol could be found for this study
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Wallwork 2006 (Continued)
Other bias Unclear risk Information was provided about the vali-
dation of the SNOT-20 instrument used
to measure quality of life. No information
was provided regarding the validationof the
scale used to evaluate nasal polyps
There is no detailed informationwithin the
study with regards to the baseline charac-
teristics of the treatment arms, apart from
a statement that there were no differences
between the 2 groups
Zeng 2011
Methods 2-arm, open-label (non-blinded), parallel-group RCT, with a 12-week duration of treat-
ment and follow-up
Participants Location: Wuhan, China
Setting of recruitment and treatment: otolaryngology department in teaching hospital
Sample size: 43
Number randomised: 22 to clarithromycin, 21 to mometasone
Number completed: 22 to clarithromycin, 21 to mometasone
Participant (baseline) characteristics:
• Age: clarithromycin 32.14 ± 15.20 years; mometasone 33.00 ± 11.30 years
• Gender: clarithromycin 63.6% male; mometasone 71.4% male
• Main diagnosis: CRS without nasal polyps
• Polyps status: 0% with nasal polyps
• Previous sinus surgery status: 0% with previous surgery
• Previous courses of steroids: not stated
Other important effect modifiers:
• Asthma: 0% in both groups
• Allergic rhinitis n (%): clarithromycin 4 (18.18%); mometasone 5 (23.81%)
Inclusion criteria:
• At least 18 years of age, Chinese, “in good health”
• CRSsNP defined as: 2 or more symptoms, 1 of which either nasal obstruction or
nasal secretion. Others include post-nasal drip, facial pain or pressure, headache and
reduction (or loss) of sense of smell. Symptoms lasting at least 12 weeks.
• No polyps on endoscopic examination
• “free of diseases that would interfere with the study”
Exclusion criteria:
• History of local or systemic medication for CRS within 4 weeks of entering study
(including steroids, antibiotics or nasal irrigation)
• Previous sinus surgery
• Immunotherapy within the previous 3 months
• Pregnant or breastfeeding women
• Cystic fibrosis, congenital ciliary dyskinesia, sinonasal fungal disease, systemic
vasculitis, granulomatous disease, tumour, immunodeficiency, nasal polyps
• Upper respiratory tract infection within 4 weeks of study
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Zeng 2011 (Continued)
• Other serious medical condition including emotional or mental problems or
acute asthma requiring hospitalisation within previous 4 weeks (see Table 1 of paper)
Interventions Intervention (n = 22): clarithromycin (Abbot China) 250 mg once daily for 12 weeks
Comparator group (n = 21):mometasone furoate nasal spray (Schering-Plough, China)
200 µg once daily for 12 weeks
Use of additional interventions (common to both treatment arm): none listed
Outcomes Primary outcomes:
1. Disease severity symptom score: 5 symptoms (nasal obstruction, rhinorrhoea, loss
of sense of smell, facial pain or pressure, headache) each scored on a VAS from 0 to 10;
combined score reported, reported at 4, 8 and 12 weeks
Secondary outcomes:
1. Endoscopy (polyps size or overall score): Lanza-Kennedy score (range 0 to 8; 0 to
4 each side) reported at 4, 8 and 12 weeks
Other outcomes reported by the study:
• Question about “overall burden of CRS symptoms” on a VAS from 0 to 10
Funding sources Funded by the programme for New Century Excellent Talents in University from State
Education Ministry (NCET-07-0326) and the National Nature Science Foundation of
China (NSFC) grants 30872847 and 81020108018 to Z. Liu
Declarations of interest Quote: “The authors have no conflicts of interest to declare pertaining to this article”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “subjects were randomly assigned
… using a random number table”
Allocation concealment (selection bias) Unclear risk Comment: there is no information regard-
ing allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label” study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label” study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “None of the patient withdrew
from the study.”
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Zeng 2011 (Continued)
Selective reporting (reporting bias) Unclear risk All key outcomes appear to be well re-
ported.No information regarding themea-
surement of adverse events was reported in
the methods section and no results for ad-
verse events are reported
No protocol could be found for this study.
Other bias Unclear risk Comment: although the endoscopic score
was validated, there was no information
about the validation of the assessment of
symptom severity outcomes
AZM: azithromycin
CRS: chronic rhinosinusitis
CRSsNP: chronic rhinosinusitis without nasal polyps
CT: computerised tomography
d: day
ENT: ear, nose and throat
EPOS: European Position Paper on Rhinosinusitis and Nasal Polyps
ESS: endoscopic sinus surgery
F: female
M: male
RCT: randomised controlled trial
SEM: standard error of the mean
SF-36: quality of life scale
SNOT-20/-22: Sinonasal Outcome Test-20/-22
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agbim 1975 DURATION: treatment and follow-up only for 7 days
Amali 2015 POPULATION: all patients underwent FESS at the start of the trial
Amini 2009 DURATION: treatment duration was 3 weeks with follow-up 8 weeks from the start of the trial
Ansari 2015 DURATION: treatment time and follow-up 4 weeks
Artigas 1989 DURATION: treatment time and follow-up 7 days
Beloborodova 1998 DURATION: treatment time and follow-up 10 days
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(Continued)
Bezerra 2014 STUDY DESIGN: not a randomised study
Bobacheva 2012 POPULATION: all participants underwent surgery within 7 days of the start of the trial
Bonfils 2015 DURATION: treatment time was 7 days with follow-up 30 days from the start of the trial
Chatzimanolis 1998 POPULATION: acute or recurrent sinusitis
DURATION: treatment time and follow-up was 10 to 12 days
Dellamonica 1994 DURATION: treatment time was 10 days with follow-up 30 days from the start of the trial
Desrosiers 2001 DURATION: treatment time was 4 weeks with follow-up 8 weeks from the start of the trial
Edelstein 1993 POPULATION: half with acute sinusitis, half with “acute exacerbation of chronic sinusitis”
DURATION: treatment time was 10 to 14 days with follow-up 30 days from the start of the trial
El’kun 1999 DURATION: treatment time and follow-up for 7 days
Fan 2014 DURATION: treatment time was 7 to 14 days with follow-up for 4 weeks from the start of the trial
Hashiba 1997 INTERVENTION: comparison of 2 antibiotics from the same class (clarithromycin and erythromycin)
and therefore not an intra-class comparison
Haxel 2015 POPULATION: all patients had surgery within 2 weeks of the start of the trial
Hiratsuka 1996 POPULATION: all participants had endoscopic sinus surgery at the start of the trial
Huck 1993 DURATION: treatment time was 10 days with follow-up for 18 days from the start of the trial
Husfeldt 1993 DURATION: treatment time and follow-up was for 7 to 14 days
IRCT201312299014N INTERVENTION: phonophoresis of erythromycin versus pulsed ultrasound
Ishiura 1995 POPULATION: sinobronchial syndrome
Jareoncharsri 2004 DURATION: treatment time was 7 days with follow-up of 21 days from the start of the trial
Jervis-Bardy 2012 DURATION: treatment time and follow-up was for 28 days
Jiang 2008 POPULATION: all patients underwent surgery at the start of the trial
DURATION: treatment time and follow-up was for 21 days
Kita 1995 STUDY DESIGN: non-randomised study
Korkmaz 2014 DURATION: treatment time and follow-up was for 8 weeks
Kunel’skaya 2008 DURATION: treatment time and follow-up was for 7 days
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(Continued)
Legent 1994 DURATION: treatment time was 9 days with follow-up of 40 days from the start of the trial
Li 2000 DURATION: follow-up time too short
Li 2002 DURATION: follow-up time too short
Li 2014 DURATION: treatment time and follow-up was for 2 weeks
Mannhardt 1980 DURATION: follow-up in control arm was for 12 days
Namyslowski 1998 DURATION: treatment time was 2 weeks with follow-up of 6 weeks from the start of the trial
NCT01825408 DURATION: study aimed to look at the durationof antibiotic treatment: 3weeks versus 6weeks treatment.
The follow-up period was 5 weeks and 8 weeks after the start of the trial
NCT02307825 POPULATION: all patients had surgery within 2 weeks of the start of the trial
Otten 1997 INTERVENTION: study included 4 treatment arms, but none were comparisons of interest: (1) placebo;
(2) xylometazoline (nasal decongestant) plus antibiotics; (3) drainage; (4) drainage plus xylometazoline
plus antibiotics
Same study as Otten 1990
Peric 2011 DURATION: treatment time and follow-up was for 2 weeks
Portier 1996 DURATION: treatment time and follow-up was for 30 days
Rachelefsky 1982 DURATION: treatment time and follow-up was for 2 weeks
Schalek 2009 POPULATION: all patients had surgery at the start of the trial
Sreenath 2015 Comparison of short-course (3 weeks) versus long-course (6 weeks) antibiotics
DURATION: patients were only followed up for 3 or 6 weeks
Sykes 1986 DURATION: duration of treatment and follow-up was 2 weeks
Varvianskaia 2013 POPULATION: all patients had surgery at the start of the trial
Videler 2008 DURATION: unclear follow-up between 8 and 12 weeks
Watanabe 2003 DURATION: treatment time and follow-up in the control arm was for 4 weeks
Wei 2011 DURATION: treatment time and follow-up was for 7 weeks
FESS: functional endoscopic sinus surgery
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Characteristics of studies awaiting assessment [ordered by study ID]
Behm 2002
Methods Unclear
Participants Unclear
Interventions Unclear
Outcomes Unclear
Notes “Health resource utilization: moxifloxacin compared to levofloxacin and amoxicillin clavulanate in reducing ”practice
time use“ in the treatment of sinusitis”
Awaiting receipt of paper
Jiang 2001
Methods Randomised controlled trial
Participants Patients with chronic sinusitis due to undergo surgery
Interventions Amoxicillin-clavulanate potassium therapy versus no antibiotics
Outcomes Bacteriology; it is unclear if any outcomes of interest were reported in the paper
Notes It is unclear if outcomes were reported before surgery
Awaiting receipt of full paper
Kataoka 2003
Methods Unclear
Participants People with paranasal sinusitis complicating allergic rhinitis
Interventions Unclear
Outcomes Unclear
Notes Awaiting receipt of full paper
Kim 2003
Methods Unclear
Participants Chronic sinusitis with nasal polyps and allergic rhinitis
Interventions Roxithromycin 300 mg daily versus intranasal steroids
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Kim 2003 (Continued)
Outcomes Patient symptoms and polyp size (no details on instruments used)
Notes Written to study authors for more details about trial methods and results
Ziuzio 1995
Methods Unclear
Participants Chronic purulent maxillary sinusitis
Interventions Clindamycin versus clindamycin, gentamycin or amikacin with metronidazole versus others antibiotics
Outcomes Unclear
Notes Awaiting receipt of paper
Characteristics of ongoing studies [ordered by study ID]
EUCTR 2005 (2005-004736-51)
Trial name or title ’Double-blind randomized placebo-controlled multinational, multicentre-trial on prolonged macrolide treat-
ment in patients with moderate/severe chronic rhinosinusitis’
Methods Randomised controlled trial
Participants People with moderate to severe chronic rhinosinusitis
Interventions Macrolide antibiotics versus placebo
Outcomes -
Starting date 2006
Contact information Prof V Lund
Notes Website says that the trial has completed. We contacted the study author for more information but no
information was provided
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D A T A A N D A N A L Y S E S
Comparison 1. Systemic antibiotics versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease-specific health-related
quality of life
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Macrolides (at 3 months -
end of treatment)
1 64 Mean Difference (IV, Fixed, 95% CI) -0.54 [-0.98, -0.10]
1.2 Macrolides (at 6 months
- 3 months after end of
treatment)
1 64 Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.81, 0.11]
2 Gastrointestinal disturbances 1 33 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.22, 8.50]
3 Suspected allergic reaction (rash
or skin irritation)
1 33 Risk Ratio (M-H, Fixed, 95% CI) 6.67 [0.34, 128.86]
4 Endoscopic score 1 64 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.85, 0.25]
Comparison 2. Systemic antibiotics + saline + intranasal corticosteroids versus placebo + saline + intranasal
corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity score (at 3
months - end of treatment)
1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.81, 2.79]
2 Gastrointestinal disturbances 1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.16, 7.10]
Comparison 3. Systemic antibiotics versus intranasal corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity score (at 3
months - end of treatment)
1 43 Mean Difference (IV, Fixed, 95% CI) -0.32 [-2.11, 1.47]
2 Individual symptom scores (at 3
months - end of treatment)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Nasal obstruction 1 43 Mean Difference (IV, Fixed, 95% CI) 0.34 [-0.79, 1.47]
2.2 Rhinorrhoea 1 43 Mean Difference (IV, Fixed, 95% CI) 0.22 [-0.81, 1.25]
2.3 Facial pain 1 43 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.21, 0.11]
2.4 Loss of sense of smell 1 43 Mean Difference (IV, Fixed, 95% CI) -0.83 [-1.75, 0.09]
3 Endoscopic score 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Combined swelling and
discharge
1 43 Mean Difference (IV, Fixed, 95% CI) -0.78 [-1.52, -0.04]
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3.2 Swelling 1 43 Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.86, 0.08]
3.3 Discharge 1 43 Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.97, 0.19]
Comparison 4. Systemic antibiotics versus oral steroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Gastrointestinal disturbances 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.16, 6.14]
2 Suspected allergic reaction (rash
or skin irritation)
1 28 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.20, 19.62]
3 Adverse events related to oral
steroid use: insomnia
1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.45]
Analysis 1.1. Comparison 1 Systemic antibiotics versus placebo, Outcome 1 Disease-specific health-related
quality of life.
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 1 Systemic antibiotics versus placebo
Outcome: 1 Disease-specific health-related quality of life
Study or subgroup Systemic antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Macrolides (at 3 months - end of treatment)
Wallwork 2006 29 2.34 (1.0232) 35 2.88 (0.7099) 100.0 % -0.54 [ -0.98, -0.10 ]
Subtotal (95% CI) 29 35 100.0 % -0.54 [ -0.98, -0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
2 Macrolides (at 6 months - 3 months after end of treatment)
Wallwork 2006 29 2.49 (0.9693) 35 2.84 (0.8874) 100.0 % -0.35 [ -0.81, 0.11 ]
Subtotal (95% CI) 29 35 100.0 % -0.35 [ -0.81, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
-100 -50 0 50 100
Favours antibiotics Favours placebo
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Analysis 1.2. Comparison 1 Systemic antibiotics versus placebo, Outcome 2 Gastrointestinal disturbances.
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 1 Systemic antibiotics versus placebo
Outcome: 2 Gastrointestinal disturbances
Study or subgroup Systemic antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Zele 2010 2/14 2/19 100.0 % 1.36 [ 0.22, 8.50 ]
Total (95% CI) 14 19 100.0 % 1.36 [ 0.22, 8.50 ]
Total events: 2 (Systemic antibiotics), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
Analysis 1.3. Comparison 1 Systemic antibiotics versus placebo, Outcome 3 Suspected allergic reaction
(rash or skin irritation).
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 1 Systemic antibiotics versus placebo
Outcome: 3 Suspected allergic reaction (rash or skin irritation)
Study or subgroup Systemic antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Zele 2010 2/14 0/19 100.0 % 6.67 [ 0.34, 128.86 ]
Total (95% CI) 14 19 100.0 % 6.67 [ 0.34, 128.86 ]
Total events: 2 (Systemic antibiotics), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
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Analysis 1.4. Comparison 1 Systemic antibiotics versus placebo, Outcome 4 Endoscopic score.
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 1 Systemic antibiotics versus placebo
Outcome: 4 Endoscopic score
Study or subgroup Systemic antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wallwork 2006 29 2.6 (1.077) 35 2.9 (1.1832) 100.0 % -0.30 [ -0.85, 0.25 ]
Total (95% CI) 29 35 100.0 % -0.30 [ -0.85, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours antibiotics Favours placebo
Analysis 2.1. Comparison 2 Systemic antibiotics + saline + intranasal corticosteroids versus placebo + saline
+ intranasal corticosteroids, Outcome 1 Disease severity score (at 3 months - end of treatment).
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 2 Systemic antibiotics + saline + intranasal corticosteroids versus placebo + saline + intranasal corticosteroids
Outcome: 1 Disease severity score (at 3 months - end of treatment)
Study or subgroup Systemic antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Videler 2011 14/27 10/29 100.0 % 1.50 [ 0.81, 2.79 ]
Total (95% CI) 27 29 100.0 % 1.50 [ 0.81, 2.79 ]
Total events: 14 (Systemic antibiotics), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
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Analysis 2.2. Comparison 2 Systemic antibiotics + saline + intranasal corticosteroids versus placebo + saline
+ intranasal corticosteroids, Outcome 2 Gastrointestinal disturbances.
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 2 Systemic antibiotics + saline + intranasal corticosteroids versus placebo + saline + intranasal corticosteroids
Outcome: 2 Gastrointestinal disturbances
Study or subgroup Systemic antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Videler 2011 2/27 2/29 100.0 % 1.07 [ 0.16, 7.10 ]
Total (95% CI) 27 29 100.0 % 1.07 [ 0.16, 7.10 ]
Total events: 2 (Systemic antibiotics), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
Analysis 3.1. Comparison 3 Systemic antibiotics versus intranasal corticosteroids, Outcome 1 Disease
severity score (at 3 months - end of treatment).
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 3 Systemic antibiotics versus intranasal corticosteroids
Outcome: 1 Disease severity score (at 3 months - end of treatment)
Study or subgroup Systemic antibiotics Intranasal steroids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zeng 2011 22 5.68 (2.559) 21 6 (3.348) 100.0 % -0.32 [ -2.11, 1.47 ]
Total (95% CI) 22 21 100.0 % -0.32 [ -2.11, 1.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours antibiotics Favours intranasal steroids
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Analysis 3.2. Comparison 3 Systemic antibiotics versus intranasal corticosteroids, Outcome 2 Individual
symptom scores (at 3 months - end of treatment).
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 3 Systemic antibiotics versus intranasal corticosteroids
Outcome: 2 Individual symptom scores (at 3 months - end of treatment)
Study or subgroup Systemic antibiotics Intranasal steroids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Nasal obstruction
Zeng 2011 22 2.77 (1.6) 21 2.43 (2.13) 100.0 % 0.34 [ -0.79, 1.47 ]
Subtotal (95% CI) 22 21 100.0 % 0.34 [ -0.79, 1.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Rhinorrhoea
Zeng 2011 22 2.36 (1.59) 21 2.14 (1.85) 100.0 % 0.22 [ -0.81, 1.25 ]
Subtotal (95% CI) 22 21 100.0 % 0.22 [ -0.81, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
3 Facial pain
Zeng 2011 22 0.05 (0.21) 21 0.1 (0.3) 100.0 % -0.05 [ -0.21, 0.11 ]
Subtotal (95% CI) 22 21 100.0 % -0.05 [ -0.21, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
4 Loss of sense of smell
Zeng 2011 22 0.5 (1.19) 21 1.33 (1.8) 100.0 % -0.83 [ -1.75, 0.09 ]
Subtotal (95% CI) 22 21 100.0 % -0.83 [ -1.75, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
Test for subgroup differences: Chi2 = 3.49, df = 3 (P = 0.32), I2 =14%
-10 -5 0 5 10
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Analysis 3.3. Comparison 3 Systemic antibiotics versus intranasal corticosteroids, Outcome 3 Endoscopic
score.
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 3 Systemic antibiotics versus intranasal corticosteroids
Outcome: 3 Endoscopic score
Study or subgroup Systemic antibiotics Intranasal steroids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Combined swelling and discharge
Zeng 2011 22 0.55 (0.83) 21 1.33 (1.54) 100.0 % -0.78 [ -1.52, -0.04 ]
Subtotal (95% CI) 22 21 100.0 % -0.78 [ -1.52, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
2 Swelling
Zeng 2011 22 0.23 (0.61) 21 0.62 (0.92) 100.0 % -0.39 [ -0.86, 0.08 ]
Subtotal (95% CI) 22 21 100.0 % -0.39 [ -0.86, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
3 Discharge
Zeng 2011 22 0.32 (0.57) 21 0.71 (1.23) 100.0 % -0.39 [ -0.97, 0.19 ]
Subtotal (95% CI) 22 21 100.0 % -0.39 [ -0.97, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 0.85, df = 2 (P = 0.65), I2 =0.0%
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Analysis 4.1. Comparison 4 Systemic antibiotics versus oral steroids, Outcome 1 Gastrointestinal
disturbances.
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 4 Systemic antibiotics versus oral steroids
Outcome: 1 Gastrointestinal disturbances
Study or subgroup Systemic antibiotics Oral steroids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Zele 2010 2/14 2/14 100.0 % 1.00 [ 0.16, 6.14 ]
Total (95% CI) 14 14 100.0 % 1.00 [ 0.16, 6.14 ]
Total events: 2 (Systemic antibiotics), 2 (Oral steroids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours oral steroids
Analysis 4.2. Comparison 4 Systemic antibiotics versus oral steroids, Outcome 2 Suspected allergic
reaction (rash or skin irritation).
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 4 Systemic antibiotics versus oral steroids
Outcome: 2 Suspected allergic reaction (rash or skin irritation)
Study or subgroup Systemic antibiotics Oral steroids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Zele 2010 2/14 1/14 100.0 % 2.00 [ 0.20, 19.62 ]
Total (95% CI) 14 14 100.0 % 2.00 [ 0.20, 19.62 ]
Total events: 2 (Systemic antibiotics), 1 (Oral steroids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours oral steroids
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Analysis 4.3. Comparison 4 Systemic antibiotics versus oral steroids, Outcome 3 Adverse events related to
oral steroid use: insomnia.
Review: Systemic and topical antibiotics for chronic rhinosinusitis
Comparison: 4 Systemic antibiotics versus oral steroids
Outcome: 3 Adverse events related to oral steroid use: insomnia
Study or subgroup Antibiotics Oral steroids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Zele 2010 1/14 1/14 100.0 % 1.00 [ 0.07, 14.45 ]
Total (95% CI) 14 14 100.0 % 1.00 [ 0.07, 14.45 ]
Total events: 1 (Antibiotics), 1 (Oral steroids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours oral steroids
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL Ovid MEDLINE
#1 MeSH descriptor: [Sinusitis] explode all trees
#2 MeSH descriptor: [Rhinitis] this term only
#3 MeSH descriptor: [Rhinitis, Atrophic] this term only
#4 MeSH descriptor: [Rhinitis, Vasomotor] this term only
#5 MeSH descriptor: [Paranasal Sinus Diseases] this term only
#6 MeSH descriptor: [Paranasal Sinuses] explode all trees
#7 rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis
#8 kartagener* near syndrome*
#9 inflamm* near sinus*
#10 (maxilla* or frontal*) near sinus*
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Chronic Disease] explode all trees
#13 MeSH descriptor: [Recurrence] explode all trees
#14 chronic or persis* or recurrent*
1 exp Sinusitis/
2 paranasal sinus diseases/ or rhinitis/ or rhinitis, atrophic/ or
rhinitis, vasomotor/
3 exp Paranasal Sinuses/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*).ab,ti.
6 (inflamm* adj5 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 sinus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp Recurrence/
11 (chronic or persis* or recurrent*).ab,ti.
12 9 or 10 or 11
13 8 and 12
70Systemic and topical antibiotics for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#15 #12 or #13 or #14
#16 #11 and #15
#17 CRSsNP
#18 (sinusitis or rhinitis) near (chronic or persis* or recurrent*)
#19 #16 or #17 or #18
#20 MeSH descriptor: [Nasal Polyps] explode all trees
#21 MeSH descriptor: [Nose] explode all trees
#22 MeSH descriptor: [Nose Diseases] explode all trees
#23 #21 or #22
#24 MeSH descriptor: [Polyps] explode all trees
#25 #23 and #24
#26 (nose or nasal or rhino* or rhinitis or sinus* or sinonasal) near
(papilloma* or polyp*)
#27 rhinopolyp* or CRSwNP
#28 #19 or #20 or #25 or #26 or #27
#29 MeSH descriptor: [Anti-Bacterial Agents] explode all trees
#30 MeSH descriptor: [Antibiotic Prophylaxis] explode all trees
#31 MeSH descriptor: [Lactams] explode all trees
#32 MeSH descriptor: [Quinolones] explode all trees
#33 MeSH descriptor: [Macrolides] explode all trees
#34 MeSH descriptor: [Tetracyclines] explode all trees
#35 ANTIBIOT* or ANTI next BIOT* or ANTIMICROBIAL*
or ANTI next MICROBIAL* or BACTERIOCID* or AN-
TIBACTERIAL* or ANTI next BACTERIAL*
#36 PENICILLIN* or AMOXICILLIN or AMPICILLIN or
CLAVULANIC or AMOXICLAVor AUGMENTIN or TICAR-
CILLIN or TIMENTIN or FLUCLOXACILLIN or FLU-
AMPICIL or MAGNAPEN or PIPERACILLIN or TAZOCIN
or CEPHALOSPORIN* or CEFACLOR or DISTACLOR or
CEFADROXIL or BAXAN or CEFALEXIN or CEPOREX
or KEFLEX or CEFAMANDOLE or KEFADOL or CEFA-
ZOLIN* or KEFZOL or CEFIXIME or SUPRAX or CEFO-
TAXIME or CLAFORAN or CEFOXITIN or MEFOXIN or
CEFPIROME or CEFROM or CEFPODOXIME or ORELOX
or CEFPROZIL or CEFZIL or CEFRADINE or VELOSEL
or CEFTAZIDIM or FORTUM or KEFADIM or CEF-
TRIAXONE or ROCEPHIN or CEFUROXIME or ZI-
NACEF or ZINNAT or CEFONICID or AZTREONAM
or AZACTAM or IMIPENEM or CILASTATIN or PRI-
MAXIN or MEROPENEM or TETRACYCLINE* or DE-
TECLO or DEMECLEOCYCLIN or LEDERMYCIN or
DOXYCYCLINE or VIBRAMYCIN or MINOCYCLINE or
MINOCINE or OXYTETRACYCLINE or TERRAMYCIN
or MACROLIDE* or ERYTHROMYCIN or ERYMAX or
ERYTHROCIN or ERYTHROPED or AZITHROMYCIN
or ZITHROMAX or CLARITHROMYCIN or KLARICID
or TELITHROMYCIN or KETEK or TRIMOXAZOLE or
SEPTRIN or TRIMETHOPRIM or MONOTRIM or TRI-
MOPAN or METRONIDAZOLE or FLAGYL or METROLYL
14 CRSsNP.ab,ti.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
ab,ti
16 13 or 14 or 15
17 exp Nasal Polyps/
18 exp Nose/ or exp Nose Diseases/
19 exp Polyps/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).ab,ti
22 (rhinopolyp* or CRSwNP).ab,ti.
23 16 or 17 or 20 or 21 or 22
24 exp Anti-Bacterial Agents/
25 exp Antibiotic Prophylaxis/
26 exp Lactams/
27 exp Quinolones/
28 exp Macrolides/
29 exp Tetracyclines/
30 (ANTIBIOT* or ANTI next BIOT* or ANTIMICROBIAL*
or ANTI next MICROBIAL* or BACTERIOCID* or AN-
TIBACTERIAL* or ANTI next BACTERIAL*).ab,ti
31 (PENICILLIN* or AMOXICILLIN or AMPICILLIN or
CLAVULANIC or AMOXICLAV or AUGMENTIN or TICAR-
CILLIN or TIMENTIN or FLUCLOXACILLIN or FLU-
AMPICIL or MAGNAPEN or PIPERACILLIN or TAZOCIN
or CEPHALOSPORIN* or CEFACLOR or DISTACLOR or
CEFADROXIL or BAXAN or CEFALEXIN or CEPOREX
or KEFLEX or CEFAMANDOLE or KEFADOL or CEFA-
ZOLIN* or KEFZOL or CEFIXIME or SUPRAX or CEFO-
TAXIME or CLAFORAN or CEFOXITIN or MEFOXIN or
CEFPIROME or CEFROM or CEFPODOXIME or ORELOX
or CEFPROZIL or CEFZIL or CEFRADINE or VELOSEL
or CEFTAZIDIM or FORTUM or KEFADIM or CEF-
TRIAXONE or ROCEPHIN or CEFUROXIME or ZI-
NACEF or ZINNAT or CEFONICID or AZTREONAM
or AZACTAM or IMIPENEM or CILASTATIN or PRI-
MAXIN or MEROPENEM or TETRACYCLINE* or DE-
TECLO or DEMECLEOCYCLIN or LEDERMYCIN or
DOXYCYCLINE or VIBRAMYCIN or MINOCYCLINE or
MINOCINE or OXYTETRACYCLINE or TERRAMYCIN
or MACROLIDE* or ERYTHROMYCIN or ERYMAX or
ERYTHROCIN or ERYTHROPED or AZITHROMYCIN
or ZITHROMAX or CLARITHROMYCIN or KLARICID
or TELITHROMYCIN or KETEK or TRIMOXAZOLE or
SEPTRIN or TRIMETHOPRIM or MONOTRIM or TRI-
MOPAN or METRONIDAZOLE or FLAGYL or METROLYL
or PHENOXYMETHYLPENICILLIN or SULFAMETHOXA-
ZOLE or OXACILLIN or CEPHALOTHIN or SULBACTAM
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or PHENOXYMETHYLPENICILLIN or SULFAMETHOXA-
ZOLE or OXACILLIN or CEPHALOTHIN or SULBACTAM
or OFLOXACIN or CLINDAMYCIN or GENTAMYCIN or
VANCOMYCIN
#37 cyclosporin* orChlortetracycline or Lymecycline orMethacy-
cline orRolitetracycline or lactam* or quinolone* orCarbapenem*
or Thienamycins or cephalosporin* or cefamandole or Cefazolin
or Cefonicid or Cefsulodin or Cephacetrile or Cephalexin or
Cephaloridine or Cephamycin* or Monobactam* or Aztreonam
or Moxalactam or Amdinocillin or Cyclacillin or Methicillin or
Nafcillin or Oxacillin or Sulbactam
#38 Nalidixic or Nedocromil or Oxolinic or Carteolol or Flu-
oroquinolones or Ciprofloxacin or Enoxacin or Norfloxacin or
Ofloxacin or Pefloxacin or Cofactor
#39 Amphotericin or Antimycin or Brefeldin or Bryostatin* or
Candicidin or Epothilone* or Ketolide* or Roxithromycin or Fil-
ipin or Ivermectin or Josamycin or Leucomycins or Kitasamycin
or Spiramycin or Lucensomycin or Maytansine or Mepartricin
or Miocamycin or Natamycin or Nystatin or Oleandomycin or
Troleandomycin or Oligomycin* or Rutamycin or Sirolimus or
Tacrolimus or Tylosin
#40 #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #
37 or #38 or #39
#41 #40 and #28
or OFLOXACIN or CLINDAMYCIN or GENTAMYCIN or
VANCOMYCIN).ab,ti
32 (cyclosporin* or Chlortetracycline or Lymecycline orMethacy-
cline orRolitetracycline or lactam* or quinolone* orCarbapenem*
or Thienamycins or cephalosporin* or cefamandole or Cefazolin
or Cefonicid or Cefsulodin or Cephacetrile or Cephalexin or
Cephaloridine or Cephamycin* or Monobactam* or Aztreonam
or Moxalactam or Amdinocillin or Cyclacillin or Methicillin or
Nafcillin or Oxacillin or Sulbactam).ab,ti
33 (Nalidixic or Nedocromil or Oxolinic or Carteolol or Flu-
oroquinolones or Ciprofloxacin or Enoxacin or Norfloxacin or
Ofloxacin or Pefloxacin or Cofactor).ab,ti
34 (Amphotericin or Antimycin or Brefeldin or Bryostatin* or
Candicidin or Epothilone* or Ketolide* or Roxithromycin or Fil-
ipin or Ivermectin or Josamycin or Leucomycins or Kitasamycin
or Spiramycin or Lucensomycin or Maytansine or Mepartricin
or Miocamycin or Natamycin or Nystatin or Oleandomycin or
Troleandomycin or Oligomycin* or Rutamycin or Sirolimus or
Tacrolimus or Tylosin).ab,ti
35 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36 23 and 35
Ovid Embase Trial registries (via CRS)
1 exp sinusitis/ or paranasal sinus disease/
2 atrophic rhinitis/ or chronic rhinitis/ or rhinosinusitis/ or vaso-
motor rhinitis/
3 exp paranasal sinus/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).tw
5 (kartagener* adj3 syndrome*).tw.
6 (inflamm* adj5 sinus*).tw.
7 ((maxilla* or frontal*) adj3 sinus*).tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp recurrent disease/
11 (chronic or persis* or recurrent*).tw.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.tw.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
tw
16 13 or 14 or 15
17 exp nose polyp/
18 exp nose disease/ or exp nose/
19 exp polyp/
ClinicalTrials.gov
Condition: rhinitis OR sinusitis OR rhinosinusitis OR (nose
AND polyp*) OR (nasal AND polyp*) OR CRSsNP OR CR-
SwNP OR CRS
ICTRP
Title: rhinitis OR sinusitis OR rhinosinusitis OR CRSsNP OR
CRSwNP OR CR
OR
All: (nose AND polyp*) OR (nasal AND polyp*)
NB These searches were run from 1 March 2015 to 11 August 2015,
when these terms were last searched to populate the Cochrane ENT
trials register in CRS
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20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).tw
22 (rhinopolyp* or CRSwNP).tw.
23 16 or 17 or 20 or 21 or 22
24 exp antiinfective agent/
25 exp antibiotic prophylaxis/
26 exp lactam/
27 exp quinolone derivative/
28 exp macrolide/
29 exp tetracycline derivative/
30 (ANTIBIOT* or (ANTI adj3BIOT*) orANTIMICROBIAL*
or (ANTI adj3 MICROBIAL*) or BACTERIOCID* or AN-
TIBACTERIAL* or (ANTI adj3 BACTERIAL*)).tw
31 (PENICILLIN* or AMOXICILLIN or AMPICILLIN or
CLAVULANIC or AMOXICLAVor AUGMENTIN or TICAR-
CILLIN or TIMENTIN or FLUCLOXACILLIN or FLU-
AMPICIL or MAGNAPEN or PIPERACILLIN or TAZOCIN
or CEPHALOSPORIN* or CEFACLOR or DISTACLOR or
CEFADROXIL or BAXAN or CEFALEXIN or CEPOREX
or KEFLEX or CEFAMANDOLE or KEFADOL or CEFA-
ZOLIN* or KEFZOL or CEFIXIME or SUPRAX or CEFO-
TAXIME or CLAFORAN or CEFOXITIN or MEFOXIN or
CEFPIROME or CEFROM or CEFPODOXIME or ORELOX
or CEFPROZIL or CEFZIL or CEFRADINE or VELOSEL
or CEFTAZIDIM or FORTUM or KEFADIM or CEF-
TRIAXONE or ROCEPHIN or CEFUROXIME or ZI-
NACEF or ZINNAT or CEFONICID or AZTREONAM
or AZACTAM or IMIPENEM or CILASTATIN or PRI-
MAXIN or MEROPENEM or TETRACYCLINE* or DE-
TECLO or DEMECLEOCYCLIN or LEDERMYCIN or
DOXYCYCLINE or VIBRAMYCIN or MINOCYCLINE or
MINOCINE or OXYTETRACYCLINE or TERRAMYCIN
or MACROLIDE* or ERYTHROMYCIN or ERYMAX or
ERYTHROCIN or ERYTHROPED or AZITHROMYCIN
or ZITHROMAX or CLARITHROMYCIN or KLARICID
or TELITHROMYCIN or KETEK or TRIMOXAZOLE or
SEPTRIN or TRIMETHOPRIM or MONOTRIM or TRI-
MOPAN or METRONIDAZOLE or FLAGYL or METROLYL
or PHENOXYMETHYLPENICILLIN or SULFAMETHOXA-
ZOLE or OXACILLIN or CEPHALOTHIN or SULBACTAM
or OFLOXACIN or CLINDAMYCIN or GENTAMYCIN or
VANCOMYCIN).tw
32 (cyclosporin* or Chlortetracycline or Lymecycline orMethacy-
cline orRolitetracycline or lactam* or quinolone* orCarbapenem*
or Thienamycins or cephalosporin* or cefamandole or Cefazolin
or Cefonicid or Cefsulodin or Cephacetrile or Cephalexin or
Cephaloridine or Cephamycin* or Monobactam* or Aztreonam
or Moxalactam or Amdinocillin or Cyclacillin or Methicillin or
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Nafcillin or Oxacillin or Sulbactam).tw
33 (Nalidixic or Nedocromil or Oxolinic or Carteolol or Flu-
oroquinolones or Ciprofloxacin or Enoxacin or Norfloxacin or
Ofloxacin or Pefloxacin or Cofactor).tw
34 (Amphotericin or Antimycin or Brefeldin or Bryostatin* or
Candicidin or Epothilone* or Ketolide* or Roxithromycin or Fil-
ipin or Ivermectin or Josamycin or Leucomycins or Kitasamycin
or Spiramycin or Lucensomycin or Maytansine or Mepartricin
or Miocamycin or Natamycin or Nystatin or Oleandomycin or
Troleandomycin or Oligomycin* or Rutamycin or Sirolimus or
Tacrolimus or Tylosin).tw
35 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36 23 and 35
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
74Systemic and topical antibiotics for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’drop-outs’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on
mean polyps score if available]
• Previous sinus surgery status: [x% with previous surgery]
• Previous courses of steroids: [add info on mean number of
courses if available]
• Other important effect modifiers, if applicable (e.g. aspirin
sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms)
:
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects: [review specific]
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Secondary outcomes:
• Health-related quality of life, generic
• [Other review specific, pre-specified adverse events]
• [Other review specific, pre-specified adverse events]
• Endoscopy (polyps size or overall score)
• CT scan
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
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Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
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(Continued)
name/range)
Smell (reduc-
tion)
(instrument
name/range)
Headache
(instrument
name/range)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
CT score
(instrument
name/range)
Comments:
Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/nose
bleed
INCS
Saline irrigation
Local irritation
(sore throat, oral
thrush, discom-
fort)
INCS
Saline irrigation
78Systemic and topical antibiotics for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Os-
teoporosis (min-
imum 6months)
INCS
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
Mood
disturbances
OCS
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
iting, stomach ir-
ritation)
OCS
Antibiotics
Insomnia OCS
Os-
teoporosis (min-
imum 6months)
INCS
OCS
Discomfort Saline irrigation
Skin irritation Antibiotics
Anaphylaxis
or other serious
allergic reactions
such as Stevens-
Johnson
Antibiotics
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As part of the discussions about the use of a total symptoms score we noted that many papers within the suite of reviews did not present
information for all four elements of the EPOS criteria for defining chronic rhinosinusitis (EPOS 2012). In particular, many studies
that only included patients with nasal polyps did not present information on facial pressure or pain. We made the decision that where
individual symptoms were recorded, they should be presented within the outcome of disease severity symptom score within the paper
as this information would be useful for the reader.
We changed the definition of a short course of antibiotics during the course of review. The original definition of a short course of
antibiotics was 14 days. However, on a review of the evidence we found a study that gave antibiotics for 21 days. We felt that this
was not the same type of information as from studies that gave antibiotics for three months and that the definition of short-course
antibiotics should be extended to one month as this was a more appropriate cut-off point.
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